Author: "Y-S, Kim" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Y-S, Kim"' showing total 1,309 results

Start Over Author "Y-S, Kim"

1,309 results on '"Y-S, Kim"'

1. Regulation of cerebral blood flow boosts precise brain targeting of vinpocetine-derived ionizable-lipidoid nanoparticles

Author: Xufei Bian, Ling Yang, Dingxi Jiang, Adam J. Grippin, Yifan Ma, Shuang Wu, Linchong Wu, Xiaoyou Wang, Zhongjie Tang, Kaicheng Tang, Weidong Pan, Shiyan Dong, Betty Y. S. Kim, Wen Jiang, Zhaogang Yang, and Chong Li
Subjects: Science
Abstract: Abstract Despite advances in active drug targeting for blood-brain barrier penetration, two key challenges persist: first, attachment of a targeting ligand to the drug or drug carrier does not enhance its brain biodistribution; and second, many brain diseases are intricately linked to microcirculation disorders that significantly impede drug accumulation within brain lesions even after they cross the barrier. Inspired by the neuroprotective properties of vinpocetine, which regulates cerebral blood flow, we propose a molecular library design centered on this class of cyclic tertiary amine compounds and develop a self-enhanced brain-targeted nucleic acid delivery system. Our findings reveal that: (i) vinpocetine-derived ionizable-lipidoid nanoparticles efficiently breach the blood-brain barrier; (ii) they have high gene-loading capacity, facilitating endosomal escape and intracellular transport; (iii) their administration is safe with minimal immunogenicity even with prolonged use; and (iv) they have potent pharmacologic brain-protective activity and may synergize with treatments for brain disorders as demonstrated in male APP/PS1 mice.
Published: 2024
Full Text: View/download PDF

2. Response of treatment-naive brain metastases to stereotactic radiosurgery

Author: Chibawanye I. Ene, Christina Abi Faraj, Thomas H. Beckham, Jeffrey S. Weinberg, Clark R. Andersen, Ali S. Haider, Ganesh Rao, Sherise D. Ferguson, Christopher A. Alvarez-Brenkenridge, Betty Y. S. Kim, Amy B. Heimberger, Ian E. McCutcheon, Sujit S. Prabhu, Chenyang Michael Wang, Amol J. Ghia, Susan L. McGovern, Caroline Chung, Mary Frances McAleer, Martin C. Tom, Subha Perni, Todd A. Swanson, Debra N. Yeboa, Tina M. Briere, Jason T. Huse, Gregory N. Fuller, Frederick F. Lang, Jing Li, Dima Suki, and Raymond E. Sawaya
Subjects: Science
Abstract: Abstract With improvements in survival for patients with metastatic cancer, long-term local control of brain metastases has become an increasingly important clinical priority. While consensus guidelines recommend surgery followed by stereotactic radiosurgery (SRS) for lesions >3 cm, smaller lesions (≤3 cm) treated with SRS alone elicit variable responses. To determine factors influencing this variable response to SRS, we analyzed outcomes of brain metastases ≤3 cm diameter in patients with no prior systemic therapy treated with frame-based single-fraction SRS. Following SRS, 259 out of 1733 (15%) treated lesions demonstrated MRI findings concerning for local treatment failure (LTF), of which 202 /1733 (12%) demonstrated LTF and 54/1733 (3%) had an adverse radiation effect. Multivariate analysis demonstrated tumor size (>1.5 cm) and melanoma histology were associated with higher LTF rates. Our results demonstrate that brain metastases ≤3 cm are not uniformly responsive to SRS and suggest that prospective studies to evaluate the effect of SRS alone or in combination with surgery on brain metastases ≤3 cm matched by tumor size and histology are warranted. These studies will help establish multi-disciplinary treatment guidelines that improve local control while minimizing radiation necrosis during treatment of brain metastasis ≤3 cm.
Published: 2024
Full Text: View/download PDF

3. Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer

Author: Chi-Ling Chiang, Yifan Ma, Ya-Chin Hou, Junjie Pan, Sin-Yu Chen, Ming-Hsien Chien, Zhi-Xuan Zhang, Wei-Hsiang Hsu, Xinyu Wang, Jingjing Zhang, Hong Li, Lili Sun, Shannon Fallen, Inyoul Lee, Xing-Yu Chen, Yeh-Shiu Chu, Chi Zhang, Tai-Shan Cheng, Wen Jiang, Betty Y. S. Kim, Eduardo Reategui, Robert Lee, Yuan Yuan, Hsiao-Chun Liu, Kai Wang, Michael Hsiao, Chi-Ying F. Huang, Yan-Shen Shan, Andrew S. Lee, and L. James Lee
Subjects: Science
Abstract: Abstract Pancreatic ductal adenocarcinoma (PDAC) tumours carry multiple gene mutations and respond poorly to treatments. There is currently an unmet need for drug carriers that can deliver multiple gene cargoes to target high solid tumour burden like PDAC. Here, we report a dual targeted extracellular vesicle (dtEV) carrying high loads of therapeutic RNA that effectively suppresses large PDAC tumours in mice. The EV surface contains a CD64 protein that has a tissue targeting peptide and a humanized monoclonal antibody. Cells sequentially transfected with plasmid DNAs encoding for the RNA and protein of interest by Transwell®-based asymmetric cell electroporation release abundant targeted EVs with high RNA loading. Together with a low dose chemotherapy drug, Gemcitabine, dtEVs suppress large orthotopic PANC-1 and patient derived xenograft tumours and metastasis in mice and extended animal survival. Our work presents a clinically accessible and scalable way to produce abundant EVs for delivering multiple gene cargoes to large solid tumours.
Published: 2023
Full Text: View/download PDF

4. Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer

Author: Shiyan Dong, Xuan Liu, Ye Bi, Yifan Wang, Abin Antony, DaeYong Lee, Kristin Huntoon, Seongdong Jeong, Yifan Ma, Xuefeng Li, Weiye Deng, Benjamin R. Schrank, Adam J. Grippin, JongHoon Ha, Minjeong Kang, Mengyu Chang, Yarong Zhao, Rongze Sun, Xiangshi Sun, Jie Yang, Jiayi Chen, Sarah K. Tang, L. James Lee, Andrew S. Lee, Lirong Teng, Shengnian Wang, Lesheng Teng, Betty Y. S. Kim, Zhaogang Yang, and Wen Jiang
Subjects: Science
Abstract: Abstract The recent success of mRNA therapeutics against pathogenic infections has increased interest in their use for other human diseases including cancer. However, the precise delivery of the genetic cargo to cells and tissues of interest remains challenging. Here, we show an adaptive strategy that enables the docking of different targeting ligands onto the surface of mRNA-loaded small extracellular vesicles (sEVs). This is achieved by using a microfluidic electroporation approach in which a combination of nano- and milli-second pulses produces large amounts of IFN-γ mRNA-loaded sEVs with CD64 overexpressed on their surface. The CD64 molecule serves as an adaptor to dock targeting ligands, such as anti-CD71 and anti-programmed cell death-ligand 1 (PD-L1) antibodies. The resulting immunogenic sEVs (imsEV) preferentially target glioblastoma cells and generate potent antitumour activities in vivo, including against tumours intrinsically resistant to immunotherapy. Together, these results provide an adaptive approach to engineering mRNA-loaded sEVs with targeting functionality and pave the way for their adoption in cancer immunotherapy applications.
Published: 2023
Full Text: View/download PDF

5. Engineering a tunable micropattern‐array assay to sort single extracellular vesicles and particles to detect RNA and protein in situ

Author: Jingjing Zhang, Xilal Y. Rima, Xinyu Wang, Luong T. H. Nguyen, Kristin Huntoon, Yifan Ma, Paola Loreto Palacio, Kim Truc Nguyen, Karunya Albert, Minh‐Dao Duong‐Thi, Nicole Walters, Kwang Joo Kwak, Min Jin Yoon, Hong Li, Jacob Doon‐Ralls, Colin L. Hisey, Daeyong Lee, Yifan Wang, Jonghoon Ha, Kelsey Scherler, Shannon Fallen, Inyoul Lee, Andre F. Palmer, Wen Jiang, Setty M. Magaña, Kai Wang, Betty Y. S. Kim, L. James Lee, and Eduardo Reátegui
Subjects: extracellular RNA, glioblastoma multiforme, heterogeneity, multiparametric, single extracellular vesicle, single lipoprotein, Cytology, QH573-671
Abstract: Abstract The molecular heterogeneity of extracellular vesicles (EVs) and the co‐isolation of physically similar particles, such as lipoproteins (LPs), confounds and limits the sensitivity of EV bulk biomarker characterization. Herein, we present a single‐EV and particle (siEVP) protein and RNA assay (siEVPPRA) to simultaneously detect mRNAs, miRNAs, and proteins in subpopulations of EVs and LPs. The siEVPPRA immobilizes and sorts particles via positive immunoselection onto micropatterns and focuses biomolecular signals in situ. By detecting EVPs at a single‐particle resolution, the siEVPPRA outperformed the sensitivities of bulk‐analysis benchmark assays for RNA and protein. To assess the specificity of RNA detection in complex biofluids, EVs from various glioma cell lines were processed with small RNA sequencing, whereby two mRNAs and two miRNAs associated with glioblastoma multiforme (GBM) were chosen for cross‐validation. Despite the presence of single‐EV‐LP co‐isolates in serum, the siEVPPRA detected GBM‐associated vesicular RNA profiles in GBM patient siEVPs. The siEVPPRA effectively examines intravesicular, intervesicular, and interparticle heterogeneity with diagnostic promise.
Published: 2023
Full Text: View/download PDF

6. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial

Author: Jing Li, Yan Wang, Chad Tang, James Welsh, Renata Ferrarotto, Mehmet Altan, Tina Cascone, Juhee Song, Marcelo V Negrao, John V Heymach, Brett W Carter, Ferdinandos Skoulidis, Yasir Y Elamin, Xiuning Le, Caroline Chung, George R Blumenschein, Nandita Guha-Thakurta, Jeffrey S Wefel, Amol J Ghia, Debra N Yeboa, Mary Frances McAleer, Kristina D Woodhouse, Susan L McGovern, Chenyang Wang, Betty Y S Kim, Jeffrey S Weinberg, and Tina M Briere
Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Background Up to 20% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis (BM), for which the current standard of care is radiation therapy with or without surgery. There are no prospective data on the safety of stereotactic radiosurgery (SRS) concurrent with immune checkpoint inhibitor therapy for BM. This is the safety cohort of the phase I/II investigator-initiated trial of SRS with nivolumab and ipilimumab for patients with BM from NSCLC.Patients and methods This single-institution study included patients with NSCLC with active BM amenable to SRS. Brain SRS and systemic therapy with nivolumab and ipilimumab were delivered concurrently (within 7 days). The endpoints were safety and 4-month intracranial progression-free survival (PFS).Results Thirteen patients were enrolled in the safety cohort, 10 of whom were evaluable for dose-limiting toxicities (DLTs). Median follow-up was 23 months (range 9.7–24.3 months). The median interval between systemic therapy and radiation therapy was 3 days. Only one patient had a DLT; hence, predefined stopping criteria were not met. In addition to the patient with DLT, three patients had treatment-related grade ≥3 adverse events, including elevated liver function tests, fatigue, nausea, adrenal insufficiency, and myocarditis. One patient had a confirmed influenza infection 7 months after initiation of protocol treatment (outside the DLT assessment window), leading to pneumonia and subsequent death from hemophagocytic lymphohistiocytosis. The estimated 4-month intracranial PFS rate was 70.7%.Conclusion Concurrent brain SRS with nivolumab/ipilimumab was safe for patients with active NSCLC BM. Preliminary analyses of treatment efficacy were encouraging for intracranial treatment response.
Published: 2023
Full Text: View/download PDF

7. P056 Factors associated with long-term prognosis in the nonmetastatic HER2-positive breast cancer. A nationwide study from Korean Breast Cancer Society

Author: Y.-J. Kang, S.J. Oh, S.Y. Bae, E.-K. Kim, Y.-J. Lee, E.H. Park, J. Jeong, H.K. Park, Y.J. Suh, and Y.-S. Kim
Subjects: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published: 2023
Full Text: View/download PDF

8. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target

Author: Nourhan Abdelfattah, Parveen Kumar, Caiyi Wang, Jia-Shiun Leu, William F. Flynn, Ruli Gao, David S. Baskin, Kumar Pichumani, Omkar B. Ijare, Stephanie L. Wood, Suzanne Z. Powell, David L. Haviland, Brittany C. Parker Kerrigan, Frederick F. Lang, Sujit S. Prabhu, Kristin M. Huntoon, Wen Jiang, Betty Y. S. Kim, Joshy George, and Kyuson Yun
Subjects: Science
Abstract: Glioblastoma (GBM) is an immune cold tumour that is refractory to immunotherapy. Here, the authors identify molecular phenotypes of immune-suppressive and -promoting myeloid cells in GBM through single cell RNA sequencing and propose S100A4 as a regulator of immune suppressive T and myeloid cells in GBM.
Published: 2022
Full Text: View/download PDF

9. Patient-reported Outcomes of Scar Impact: Comparing of Abdominoplasty, Breast Surgery, and Facial Surgery Patients

Author: Stuti P. Garg, BA, Joshua P. Weissman, BBA, Narainsai K. Reddy, MS, Jeffrey Varghese, BS, Marco F. Ellis, MD, FACS, John Y. S. Kim, MD, FACS, and Robert D. Galiano, MD, FACS
Subjects: Surgery, RD1-811
Abstract: Background:. Scarring negatively impacts patient mental health, causing worsened self-confidence, body image, and social interactions, as well as anxiety and depression. The objective of this study is to evaluate the scarring impact after facial surgery, breast surgery, and full abdominoplasty for symptoms, appearance, psychosocial health, career, and sexual well-being using validated patient-reported outcome measures. Method:. A total of 901 patients from five providers completed the SCAR-Q (covering symptoms, appearance, and psychosocial) and Career/Sexual Well-being assessments via phone or email where a higher score indicated a more positive scar perception. Results:. Of the 901 patients, 38.1% had abdominoplasty surgery, 38.1% breast reduction, 15.3% facial surgery, 4.7% breast lift, and 3.9% breast augmentation. The differences in SCAR-Q, appearance, and symptom scores between the five procedures were statistically significant. Breast augmentation SCAR-Q scores (median = 256) and facial surgery (median = 242) were significantly higher than those of abdominoplasty patients (median = 219; P = 0.003 and P = 0.001, respectively). Duration after surgery was positively correlated with improved symptom scale scores for abdominoplasty (r = 0.24, P < 0.001), breast augmentation (r = 0.71, P = 0.015), and facial surgery patients (r = 0.28, P = 0.001), but not for other procedures. Conclusions:. This study is the first to show that breast augmentation and facial surgery patients have a more positive perception of their scars in terms of appearance, symptoms, psychosocial, career, and sexual well-being impact than abdominoplasty patients. Furthermore, the data suggest that symptoms may improve over time for abdominoplasty, breast augmentation, and facial surgery patients. This study highlights the need for further follow-up, counseling, or other improvements to postoperative scar care.
Published: 2022
Full Text: View/download PDF

10. Clinical Validation of a Colorimetric Loop-Mediated Isothermal Amplification Using a Portable Device for the Rapid Detection of SARS-CoV-2

Author: Bruna W. Raddatz, Felipe J. Rabello, Rafael Benedetti, Gisleine J. Steil, Louise M. Imamura, Edson Y. S. Kim, Erika B. Santiago, Luís F. Hartmann, João V. Predebon, Bruna M. Delfino, Meri B. Nogueira, Jucélia S. dos Santos, Breno G. da Silva, Diego R. P. Nicollete, Bernardo M. M. de Almeida, Sergio R. Rogal, and Marcus V. M. Figueredo
Subjects: RT-LAMP, colorimetric, SARS-CoV-2, Point-of-Care, diagnostics, Medicine (General), R5-920
Abstract: Quick and reliable mass testing of infected people is an effective tool for the contingency of SARS-CoV-2. During the COVID-19 pandemic, Point-of-Care (POC) tests using Loop-Mediated Isothermal Amplification (LAMP) arose as a useful diagnostic tool. LAMP tests are a robust and fast alternative to Polymerase Chain Reaction (PCR), and their isothermal property allows easy incorporation into POC platforms. The main drawback of using colorimetric LAMP is the reported short-term stability of the pre-mixed reagents, as well as the relatively high rate of false-positive results. Also, low-magnitude amplification can produce a subtle color change, making it difficult to discern a positive reaction. This paper presents Hilab Molecular, a portable device that uses the Internet of Things and Artificial Intelligence to pre-analyze colorimetric data. In addition, we established manufacturing procedures to increase the stability of colorimetric RT-LAMP tests. We show that ready-to-use reactions can be stored for up to 120 days at −20 °C. Furthermore, we validated both the Hilab Molecular device and the Hilab RT-LAMP test for SARS-CoV-2 using 581 patient samples without any purification steps. We achieved a sensitivity of 92.93% and specificity of 99.42% (samples with CT ≤ 30) when compared to RT-qPCR.
Published: 2023
Full Text: View/download PDF

11. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity

Author: Christina A. von Roemeling, Yifan Wang, Yaqing Qie, Hengfeng Yuan, Hai Zhao, Xiujie Liu, Zhaogang Yang, Mingming Yang, Weiye Deng, Katelyn A. Bruno, Charles K. Chan, Andrew S. Lee, Stephen S. Rosenfeld, Kyuson Yun, Aaron J. Johnson, Duane A. Mitchell, Wen Jiang, and Betty Y. S. Kim
Subjects: Science
Abstract: Professional antigen presenting cells (APCs) are deterred from phagocytosing cancer cells that express CD47. Here, the authors show that in glioblastoma mouse models, temozolomide improves the phagocytosis effect of CD47 blockade in APCs and results in the activation of adaptive anti-tumour responses.
Published: 2020
Full Text: View/download PDF

12. Conformal and Ultra Shallow Junction Formation Achieved Using a Pulsed-Laser Annealing Process Integrated With a Modified Plasma Assisted Doping Method

Author: Seunghun Baik, Dong-Jae Kwon, Hongki Kang, Jae Eun Jang, Jaewon Jang, Y. S. Kim, and Hyuk-Jun Kwon
Subjects: Ultra-shallow junction, phosphorus, plasma assisted doping, laser annealing process, Electrical engineering. Electronics. Nuclear engineering, TK1-9971
Abstract: Recently, a shallow and conformal doping profile is required for promising 3D structured devices. In this study, we deposited the dopant phosphorus (P) using modified plasma assisted doping (PaD) followed by an annealing process to electrically activate the dopants. A rapid thermal annealing process (RTP) was the first approach tested for activation but it resulted in a deep junction (>35 nm). To reduce the junction depth, we tried the flash lamp annealing process (FLP) to shorten the annealing time. We also predicted the annealing temperature by numerical thermal analysis, which reached 1,020 °C. However, the FLP resulted in a deep junction (~ 30 nm), which was not shallow enough to suppress short channel effects. Since an even shorter annealing process was required to form a ultra-shallow junction, we tried the laser annealing process (LAP) as a promising alternative. The LAP, which had a power density of 0.3 J/cm2, increased the surface temperature up to 1,100 °C with a shallow isothermal layer. Using the LAP, we achieved a USJ with an activated surface dopant concentration of 3.86×10 19 cm-3 and a junction depth of 10 nm, which will allow further scaling-down of devices.
Published: 2020
Full Text: View/download PDF

13. Spatiotemporal Immunomodulation Using Biomimetic Scaffold Promotes Endochondral Ossification‐Mediated Bone Healing

Author: Yutong Liu, Zhaogang Yang, Lixuan Wang, Lili Sun, Betty Y. S. Kim, Wen Jiang, Yuan Yuan, and Changsheng Liu
Subjects: dexamethasone, endochondral ossification, hypoxia signaling pathway, immunomodulation, sequential release, Science
Abstract: Abstract Biomaterials play an important role in treating bone defects by promoting direct osteogenic healing through intramembranous ossification (IO). However, majority of the body's bones form via cartilaginous intermediates by endochondral ossification (EO), a process that has not been well mimicked by engineered scaffolds, thus limiting their clinical utility in treating large segmental bone defects. Here, by entrapping corticosteroid dexamethasone within biomimetic recombinant human bone morphogenetic protein (rhBMP)‐loaded porous mesoporous bioglass scaffolds and regulating their release kinetics, significant degree of ectopic bone formation through endochondral ossification is achieved. By regulating the recruitment and polarization of immune suppressive macrophage phenotypes, the scaffold promotes rapid chondrogenesis by activating Hif‐3α signaling pathway in mesenchymal stem cells, which upregulates the expression of downstream chondrogenic genes. Inhibition of Hif‐3α signaling reverses the endochondral ossification phenotype. Together, these results reveal a strategy to facilitate developmental bone growth process using immune modulating biomimetic scaffolds, thus providing new opportunities for developing biomaterials capable of inducing natural tissue regeneration.
Published: 2021
Full Text: View/download PDF

14. Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy

Author: Yifan Ma, Shiyan Dong, Xuefeng Li, Betty Y. S. Kim, Zhaogang Yang, and Wen Jiang
Subjects: extracellular vesicle, exosome, therapeutic nanoplatform, cancer therapy, drug delivery, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract: Extracellular vesicles (EVs) are cell-derived membrane particles that represent an endogenous mechanism for cell-to-cell communication. Since discovering that EVs have multiple advantages over currently available delivery platforms, such as their ability to overcome natural barriers, intrinsic cell targeting properties, and circulation stability, the potential use of EVs as therapeutic nanoplatforms for cancer studies has attracted considerable interest. To fully elucidate EVs’ therapeutic function for treating cancer, all current knowledge about cellular uptake and trafficking of EVs will be initially reviewed. In order to further improve EVs as anticancer therapeutics, engineering strategies for cancer therapy have been widely explored in the last decade, along with other cancer therapies. However, therapeutic applications of EVs as drug delivery systems have been limited because of immunological concerns, lack of methods to scale EV production, and efficient drug loading. We will review and discuss recent progress and remaining challenges in developing EVs as a delivery nanoplatform for cancer therapy.
Published: 2021
Full Text: View/download PDF

15. Environmental Factors Associated with the Eukaryotic Microbial Diversity of Ulleungdo Volcanic Island in South Korea

Author: H. S. Yun, J. H. Lee, Y. S. Choo, J. H. Pak, H. S. Kim, Y. S. Kim, and H. S. Yoon
Subjects: Applied Microbiology and Biotechnology, Microbiology
Published: 2022

16. Rapid deployment of SARS-CoV-2 testing: The CLIAHUB.

Author: Emily D Crawford, Irene Acosta, Vida Ahyong, Erika C Anderson, Shaun Arevalo, Daniel Asarnow, Shannon Axelrod, Patrick Ayscue, Camillia S Azimi, Caleigh M Azumaya, Stefanie Bachl, Iris Bachmutsky, Aparna Bhaduri, Jeremy Bancroft Brown, Joshua Batson, Astrid Behnert, Ryan M Boileau, Saumya R Bollam, Alain R Bonny, David Booth, Michael Jerico B Borja, David Brown, Bryan Buie, Cassandra E Burnett, Lauren E Byrnes, Katelyn A Cabral, Joana P Cabrera, Saharai Caldera, Gabriela Canales, Gloria R Castañeda, Agnes Protacio Chan, Christopher R Chang, Arthur Charles-Orszag, Carly Cheung, Unseng Chio, Eric D Chow, Y Rose Citron, Allison Cohen, Lillian B Cohn, Charles Chiu, Mitchel A Cole, Daniel N Conrad, Angela Constantino, Andrew Cote, Tre'Jon Crayton-Hall, Spyros Darmanis, Angela M Detweiler, Rebekah L Dial, Shen Dong, Elias M Duarte, David Dynerman, Rebecca Egger, Alison Fanton, Stacey M Frumm, Becky Xu Hua Fu, Valentina E Garcia, Julie Garcia, Christina Gladkova, Miriam Goldman, Rafael Gomez-Sjoberg, M Grace Gordon, James C R Grove, Shweta Gupta, Alexis Haddjeri-Hopkins, Pierce Hadley, John Haliburton, Samantha L Hao, George Hartoularos, Nadia Herrera, Melissa Hilberg, Kit Ying E Ho, Nicholas Hoppe, Shayan Hosseinzadeh, Conor J Howard, Jeffrey A Hussmann, Elizabeth Hwang, Danielle Ingebrigtsen, Julia R Jackson, Ziad M Jowhar, Danielle Kain, James Y S Kim, Amy Kistler, Oriana Kreutzfeld, Jessie Kulsuptrakul, Andrew F Kung, Charles Langelier, Matthew T Laurie, Lena Lee, Kun Leng, Kristoffer E Leon, Manuel D Leonetti, Sophia R Levan, Sam Li, Aileen W Li, Jamin Liu, Heidi S Lubin, Amy Lyden, Jennifer Mann, Sabrina Mann, Gorica Margulis, Diana M Marquez, Bryan P Marsh, Calla Martyn, Elizabeth E McCarthy, Aaron McGeever, Alexander F Merriman, Lauren K Meyer, Steve Miller, Megan K Moore, Cody T Mowery, Tanzila Mukhtar, Lusajo L Mwakibete, Noelle Narez, Norma F Neff, Lindsay A Osso, Diter Oviedo, Suping Peng, Maira Phelps, Kiet Phong, Peter Picard, Lindsey M Pieper, Neha Pincha, Angela Oliveira Pisco, Angela Pogson, Sergei Pourmal, Robert R Puccinelli, Andreas S Puschnik, Elze Rackaityte, Preethi Raghavan, Madhura Raghavan, James Reese, Joseph M Replogle, Hanna Retallack, Helen Reyes, Donald Rose, Marci F Rosenberg, Estella Sanchez-Guerrero, Sydney M Sattler, Laura Savy, Stephanie K See, Kristin K Sellers, Paula Hayakawa Serpa, Maureen Sheehy, Jonathan Sheu, Sukrit Silas, Jessica A Streithorst, Jack Strickland, Doug Stryke, Sara Sunshine, Peter Suslow, Renaldo Sutanto, Serena Tamura, Michelle Tan, Jiongyi Tan, Alice Tang, Cristina M Tato, Jack C Taylor, Iliana Tenvooren, Erin M Thompson, Edward C Thornborrow, Eric Tse, Tony Tung, Marc L Turner, Victoria S Turner, Rigney E Turnham, Mary J Turocy, Trisha V Vaidyanathan, Ilia D Vainchtein, Manu Vanaerschot, Sara E Vazquez, Anica M Wandler, Anne Wapniarski, James T Webber, Zara Y Weinberg, Alexandra Westbrook, Allison W Wong, Emily Wong, Gajus Worthington, Fang Xie, Albert Xu, Terrina Yamamoto, Ying Yang, Fauna Yarza, Yefim Zaltsman, Tina Zheng, and Joseph L DeRisi
Subjects: Immunologic diseases. Allergy, RC581-607, Biology (General), QH301-705.5
Published: 2020
Full Text: View/download PDF

17. Lateral and Inferior Implant Malposition in Prosthetic Breast Reconstruction: Incidence and Risk Factors

Author: Megan Fracol, MD, Cecil S. Qiu, MD, Wen-Kuan Chiu, MD, Lauren N. Feld, BS, Nikita Shah, BA, and John Y. S. Kim, MD, FACS
Subjects: Surgery, RD1-811
Abstract: Background:. Implant malposition is one of the most common causes for revision after prosthetic breast reconstruction. There is a paucity of research on the incidence, etiology and risk factors for implant malposition in this setting. Methods:. Retrospective review of a single surgeon’s prosthetic breast reconstructions was performed. Variables collected included age, BMI, radiation, chemotherapy, implant characteristics and malposition location (inferior or lateral). Binary logistic regression identified risk factors for malposition. Chi-square test assessed malposition rate as a function of implant volume to BMI subgroups. Results:. Of 836 breasts, 82 (9.8%) exhibited implant malposition. Risk factors for any malposition were older age (OR 1.05, 95% CI 1.02-1.07), BMI
Published: 2020
Full Text: View/download PDF

18. Evolving affinity between Coulombic reversibility and hysteretic phase transformations in nano-structured silicon-based lithium-ion batteries

Author: K. Ogata, S. Jeon, D.-S. Ko, I. S. Jung, J. H. Kim, K. Ito, Y. Kubo, K. Takei, S. Saito, Y.-H. Cho, H. Park, J. Jang, H.-G. Kim, J.-H. Kim, Y. S. Kim, W. Choi, M. Koh, K. Uosaki, S. G. Doo, Y. Hwang, and S. Han
Subjects: Science
Abstract: Using silicon electrodes could improve lithium ion battery storage capacities, but irreversible side reactions during cycling rapidly degrade current batteries. Here, the authors studied silicon-rich electrode phase transitions and how such transitions may benefit the rechargeable cell systems.
Published: 2018
Full Text: View/download PDF

19. Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy

Author: Yifei Lu, Kristin Huntoon, DaeYong Lee, Yifan Wang, JongHoon Ha, Yaqing Qie, Xuefeng Li, Benjamin R. Schrank, Shiyan Dong, Thomas D. Gallup, Minjeong Kang, Hai Zhao, Yi An, Zhaogang Yang, Jing Li, Betty Y. S. Kim, and Wen Jiang
Subjects: Biomedical Engineering, General Materials Science, Bioengineering, Electrical and Electronic Engineering, Condensed Matter Physics, Atomic and Molecular Physics, and Optics
Published: 2022

20. Beyond 30 Days: A Risk Calculator for Longer Term Outcomes of Prosthetic Breast Reconstruction

Author: Jordan T. Blough, MD, Michael M. Vu, MD, Cecil S. Qiu, BA, Alexei S. Mlodinow, MBA, Nima Khavanin, MD, Neil A. Fine, MD, and John Y. S. Kim, MD
Subjects: Surgery, RD1-811
Abstract: Background:. Despite growing use of surgical risk calculators, many are limited to 30-day outcomes due to the constraints of their underlying datasets. Because complications of breast reconstruction can occur well beyond 30 days after surgery, we endeavored to expand the Breast Reconstruction Risk Assessment (BRA) Score to prediction of 1-year complications after primary prosthetic breast reconstruction. Methods:. We examined our prospective intrainstitutional database of prosthetic breast reconstructions from 2004 to 2015. Patients without 1-year follow-up were excluded. Pertinent patient variables include those enumerated in past iterations of the BRA Score. Outcomes of interest include seroma, surgical site infection (SSI), implant exposure, and explantation occurring within 1 year of tissue expander placement. Risk calculators were developed for each outcome using multivariate logistic regression models and made available online at www.BRAScore.org. Internal validity was assessed using C-statistic, Hosmer-Lemeshow test, and Brier score. Results:. Nine-hundred three patients met inclusion criteria. Within 1-year, 3.0% of patients experienced seroma, 6.9% infection, 7.1% implant exposure, and 13.2% explantation. Thirty-day, 90-day, and 180-day windows captured 17.6%, 39.5%, and 59.7% of explantations, respectively. One-year risk calculators were developed for each complication of interest, and all demonstrated good internal validity: C-statistics for the 5 models ranged from 0.674 to 0.739, Hosmer-Lemeshow tests were uniformly nonsignificant, and Brier scores ranged from 0.027 to 0.154. Conclusions:. Clinically significant complications of prosthetic breast reconstruction usually occur beyond the 30-day window following tissue expander placement. To better reflect long-term patient experiences, the BRA Score was enhanced with individualized risk models that predicted 1-year complications after prosthetic reconstruction (BRA Score XL). All models performed as well as, if not better than, the original BRA Score models and other popular risk calculators such as the CHA2DS2VASc Score. The patient-friendly BRA Score XL risk calculator is available at www.brascore.org to facilitate operative decision-making and heighten the informed consent process for patients.
Published: 2018
Full Text: View/download PDF

21. Engineering nanomaterial physical characteristics for cancer immunotherapy

Author: DaeYong Lee, Kristin Huntoon, Jacques Lux, Betty Y. S. Kim, and Wen Jiang
Published: 2023

22. Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles

Author: Xuefeng Li, Sina Khorsandi, Yifan Wang, Julien Santelli, Kristin Huntoon, Nhu Nguyen, Mingming Yang, DaeYong Lee, Yifei Lu, Ruoqi Gao, Betty Y. S. Kim, Caroline de Gracia Lux, Robert F. Mattrey, Wen Jiang, and Jacques Lux
Subjects: Microbubbles, Nucleotides, Biomedical Engineering, Antigen-Presenting Cells, Membrane Proteins, Bioengineering, Condensed Matter Physics, Nucleotidyltransferases, Atomic and Molecular Physics, and Optics, Nanostructures, Mice, Neoplasms, Animals, General Materials Science, Immunotherapy, Electrical and Electronic Engineering
Abstract: The cytosolic innate immune sensor cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway is crucial for priming adaptive antitumour immunity through antigen-presenting cells (APCs). Natural agonists, such as cyclic dinucleotides (CDNs), activate the cGAS-STING pathway, but their clinical translation is impeded by poor cytosolic entry and serum stability, low specificity and rapid tissue clearance. Here we developed an ultrasound (US)-guided cancer immunotherapy platform using nanocomplexes composed of 2'3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) electrostatically bound to biocompatible branched cationic biopolymers that are conjugated onto APC-targeting microbubbles (MBs). The nanocomplex-conjugated MBs engaged with APCs and efficiently delivered cGAMP into the cytosol via sonoporation, resulting in activation of cGAS-STING and downstream proinflammatory pathways that efficiently prime antigen-specific T cells. This bridging of innate and adaptive immunity inhibited tumour growth in both localized and metastatic murine cancer models. Our findings demonstrate that targeted local activation of STING in APCs under spatiotemporal US stimulation results in systemic antitumour immunity and improves the therapeutic efficacy of checkpoint blockade, thus paving the way towards novel image-guided strategies for targeted immunotherapy of cancer.
Published: 2022

23. ESICM LIVES 2016: part one

Author: L. Bos, L. Schouten, L. van Vught, M. Wiewel, D. Ong, O. Cremer, A. Artigas, I. Martin-Loeches, A. Hoogendijk, T. van der Poll, J. Horn, N. Juffermans, M. Schultz, N. de Prost, T. Pham, G. Carteaux, A. Mekontso Dessap, C. Brun-Buisson, E. Fan, G. Bellani, J. Laffey, A. Mercat, L. Brochard, B. Maitre, LUNG SAFE investigators and the ESICM study group, P. A. Howells, D. R. Thickett, C. Knox, D. P. Park, F. Gao, O. Tucker, T. Whitehouse, D. F. McAuley, G. D. Perkins, LUNG SAFE Investigators and the ESICM Trials Group, L. Pisani, J. P. Roozeman, F. D. Simonis, A. Giangregorio, L. R. Schouten, S. M. Van der Hoeven, A. Serpa Neto, E. Festic, A. M. Dondorp, S. Grasso, L. D. Bos, M. J. Schultz, M. Koster-Brouwer, D. Verboom, B. Scicluna, K. van de Groep, J. Frencken, M. Bonten, J. I. Ko, K. S. Kim, G. J. Suh, W. Y. Kwon, K. Kim, J. H. Shin, O. T. Ranzani, E. Prina, R. Menendez, A. Ceccato, R. Mendez, C. Cilloniz, A. Gabarrus, M. Ferrer, A. Torres, A. Urbano, L. A. Zhang, D. Swigon, F. Pike, R. S. Parker, G. Clermont, C. Scheer, S. O. Kuhn, A. Modler, M. Vollmer, C. Fuchs, K. Hahnenkamp, S. Rehberg, M. Gründling, A. Taggu, N. Darang, N. Öveges, I. László, K. Tánczos, M. Németh, G. Lebák, B. Tudor, D. Érces, J. Kaszaki, W. Huber, D. Trásy, Z. Molnár, G. Ferrara, V. S. Kanoore Edul, H. S. Canales, E. Martins, C. Canullán, G. Murias, M. O. Pozo, J. F. Caminos Eguillor, M. G. Buscetti, C. Ince, A. Dubin, H. D. Aya, A. Rhodes, N. Fletcher, R. M. Grounds, M. Cecconi, M. Jacquet-Lagrèze, M. Riche, R. Schweizer, P. Portran, W. Fornier, M. Lilot, J. Neidecker, J. L. Fellahi, A. Escoresca-Ortega, A. Gutiérrez-Pizarraya, L. Charris-Castro, Y. Corcia-Palomo, E. Fernandez-Delgado, J. Garnacho-Montero, C. Roger, L. Muller, L. Elotmani, J. Lipman, J. Y. Lefrant, J. A. Roberts, R. Muñoz-Bermúdez, M. Samper, C. Climent, F. Vasco, V. Sara, S. Luque, N. Campillo, S. Grau Cerrato, J. R. Masclans, F. Alvarez-Lerma, S. Carvalho Brugger, G. Jimenez Jimenez, M. Miralbés Torner, J. Trujillano Cabello, B. Balsera Garrido, X. Nuvials Casals, F. Barcenilla Gaite, M. Vallverdú Vidal, M. Palomar Martínez, V. Gusarov, D. Shilkin, M. Dementienko, E. Nesterova, N. Lashenkova, A. Kuzovlev, M. Zamyatin, A. Demoule, S. Carreira, S. Lavault, O. Palancca, E. Morawiec, J. Mayaux, I. Arnulf, T. Similowski, B. S. Rasmussen, R. G. Maltesen, M. Hanifa, S. Pedersen, S. R. Kristensen, R. Wimmer, M. Panigada, G. Li Bassi, T. Kolobow, A. Zanella, M. Cressoni, L. Berra, V. Parrini, H. Kandil, G. Salati, S. Livigni, A. Amatu, A. Andreotti, F. Tagliaferri, G. Moise, G. Mercurio, A. Costa, A. Vezzani, S. Lindau, J. Babel, M. Cavana, D. Consonni, A. Pesenti, L. Gattinoni, for the GRAVITY-VAP TRIAL NETWORK, P. Mansouri, F. Zand, L. Zahed, F. Dehghanrad, M. Bahrani, M. Ghorbani, B. Cambiaghi, O. Moerer, T. Mauri, N. Kunze-Szikszay, C. Ritter, M. Quintel, L. M. Vilander, M. A. Kaunisto, S. T. Vaara, V. Pettilä, FINNAKI Study Group, J. L. G. Haitsma Mulier, S. Rozemeijer, A. M. E. Spoelstra-de Man, P. E. Elbers, P. R. Tuinman, M. C. de Waard, H. M. Oudemans-van Straaten, A. M. A. Liberatore, R. B. Souza, A. M. C. R. P. F. Martins, J. C. F. Vieira, I. H. J. Koh, M. Galindo Martínez, R. Jiménez Sánchez, L. Martínez Gascón, M. D. Rodríguez Mulero, A. Ortín Freire, A. Ojados Muñoz, S. Rebollo Acebes, Á. Fernández Martínez, S. Moreno Aliaga, L. Herrera Para, J. Murcia Payá, F. Rodríguez Mulero, P. Guerci, Y. Ince, P. Heeman, B. Ergin, Z. Uz, M. Massey, R. Papatella, E. Bulent, F. Toraman, E. R. Longbottom, H. D. Torrance, H. C. Owen, C. J. Hinds, R. M. Pearse, M. J. O’Dywer, Z. Trogrlic, M. van der Jagt, H. Lingsma, H. H. Ponssen, J. F. Schoonderbeek, F. Schreiner, S. J. Verbrugge, S. Duran, T. van Achterberg, J. Bakker, D. A. M. P. J. Gommers, E. Ista, A. Krajčová, P. Waldauf, F. Duška, A. Shah, N. Roy, S. McKechnie, C. Doree, S. Fisher, S. J. Stanworth, J. F. Jensen, D. Overgaard, M. H. Bestle, D. F. Christensen, I. Egerod, The RAPIT Group, A. Pivkina, I. Zhivotneva, N. Pasko, A. Alklit, R. L. Hansen, H. Knudsen, L. B. Grode, The RAPIT group, M. Hravnak, L. Chen, A. Dubrawski, M. R. Pinsky, S. M. Parry, L. D. Knight, B. C. Connolly, C. E. Baldwin, Z. A. Puthucheary, L. Denehy, N. Hart, P. E. Morris, J. Mortimore, C. L. Granger, H. I. Jensen, R. Piers, B. Van den Bulcke, J. Malmgren, V. Metaxa, A. K. Reyners, M. Darmon, K. Rusinova, D. Talmor, A. P. Meert, L. Cancelliere, L. Zubek, P. Maia, A. Michalsen, J. Decruyenaere, E. Kompanje, S. Vanheule, E. Azoulay, S. Vansteelandt, D. Benoit, C. Ryan, D. Dawson, J. Ball, K. Noone, B. Aisling, S. Prudden, A. Ntantana, D. Matamis, S. Savvidou, M. Giannakou, M. Gouva, G. Nakos, V. Koulouras, J. Aron, G. Lumley, D. Milliken, K. Dhadwal, B. A. McGrath, S. J. Lynch, B. Bovento, G. Sharpe, E. Grainger, S. Pieri-Davies, S. Wallace, B. McGrath, M. Jung, J. Cho, H. Park, G. Suh, O. Kousha, J. Paddle, L. Gamrin Gripenberg, M. Sundström Rehal, J. Wernerman, O. Rooyackers, H. J. de Grooth, W. P. Choo, A. M. Spoelstra-de Man, E. L. Swart, L. Talan, G. Güven, N. D. Altıntas, M. Padar, G. Uusvel, L. Starkopf, J. Starkopf, A. Reintam Blaser, M. S. Kalaiselvan, A. S. Arunkumar, M. K. Renuka, R. L. Shivkumar, M. Volbeda, D. ten Kate, M. Hoekstra, J. M. van der Maaten, M. W. Nijsten, A. Komaromi, Å. Norberg, M. Smedberg, M. Mori, L. Pettersson, M. Theodorakopoulou, T. Christodoulopoulou, A. Diamantakis, F. Frantzeskaki, M. Kontogiorgi, E. Chrysanthopoulou, M. Lygnos, C. Diakaki, A. Armaganidis, K. Gundogan, E. Dogan, R. Coskun, S. Muhtaroglu, M. Sungur, T. Ziegler, M. Guven, A. Kleyman, W. Khaliq, D. Andreas, M. Singer, R. Meierhans, R. Schuepbach, I. De Brito-Ashurst, G. Sabetian, R. Nikandish, F. Hagar, M. Masjedi, B. Maghsudi, A. Vazin, E. Asadpour, K. C. Kao, L. C. Chiu, C. Y. Hung, C. H. Chang, S. H. Li, H. C. Hu, S. El Maraghi, M. Ali, D. Rageb, M. Helmy, J. Marin-Corral, C. Vilà, A. Vàzquez, I. Martín-Loeches, E. Díaz, J. C. Yébenes, A. Rodriguez, F. Álvarez-Lerma, H1N1 SEMICYUC/GETGAG Working Group, N. Varga, A. Cortina-Gutiérrez, L. Dono, M. Martínez-Martínez, C. Maldonado, E. Papiol, M. Pérez-Carrasco, R. Ferrer, K. Nweze, B. Morton, I. Welters, M. Houard, B. Voisin, G. Ledoux, S. Six, E. Jaillette, S. Nseir, S. Romdhani, R. Bouneb, D. Loghmari, N. Ben Aicha, J. Ayachi, K. Meddeb, I. Chouchène, A. Khedher, M. Boussarsar, K. S. Chan, W. L. Yu, J. Nolla, L. Vidaur, J. Bonastre, B. Suberbiola, J. E. Guerrero, H1N1 SEMICYUC/GETGAG working group, N. Ramon Coll, G. Jiménez Jiménez, J. Codina Calero, M. García, M. C. de la Torre, E. Vendrell, E. Palomera, E. Güell, M. Serra-Prat, J. F. Bermejo-Martín, J. Almirall, E. Tomas, A. Escoval, F. Froe, M. H. Vitoria Pereira, N. Velez, E. Viegas, E. Filipe, C. Groves, M. Reay, A. Ballin, F. Facchin, G. Sartori, F. Zarantonello, E. Campello, C. M. Radu, S. Rossi, C. Ori, P. Simioni, N. Umei, I. Shingo, A. C. Santos, C. Candeias, I. Moniz, R. Marçal, Z. Costa e Silva, J. M. Ribeiro, J. F. Georger, J. P. Ponthus, M. Tchir, V. Amilien, M. Ayoub, E. Barsam, G. Martucci, G. Panarello, F. Tuzzolino, G. Capitanio, V. Ferrazza, T. Carollo, L. Giovanni, A. Arcadipane, M. López Sánchez, M. A. González-Gay, F. J. Llorca Díaz, M. I. Rubio López, E. Zogheib, L. Villeret, J. Nader, M. Bernasinski, P. Besserve, T. Caus, H. Dupont, P. Morimont, S. Habran, R. Hubert, T. Desaive, F. Blaffart, N. Janssen, J. Guiot, A. Pironet, P. Dauby, B. Lambermont, T. Pettenuzzo, G. Citton, C. Kirakli, O. Ediboglu, S. Ataman, M. Yarici, F. Tuksavul, S. Keating, A. Gibson, M. Gilles, M. Dunn, G. Price, N. Young, P. Remeta, P. Bishop, M. D. Fernández Zamora, J. Muñoz-Bono, E. Curiel-Balsera, E. Aguilar-Alonso, R. Hinojosa, A. Gordillo-Brenes, J. A. Arboleda-Sánchez, ARIAM-CARDIAC SURGERY PROJECT AUTHORS, I. Skorniakov, D. Vikulova, C. Whiteley, O. Shaikh, A. Jones, M. Ostermann, L. Forni, M. Scott, J. Sahatjian, W. Linde-Zwirble, D. Hansell, P. Laoveeravat, N. Srisawat, M. Kongwibulwut, S. Peerapornrattana, N. Suwachittanont, T. O. Wirotwan, P. Chatkaew, P. Saeyub, K. Latthaprecha, K. Tiranathanagul, S. Eiam-ong, J. A. Kellum, R. E. Berthelsen, A. Perner, A. E. K. Jensen, J. U. Jensen, D. J. Gebhard, J. Price, C. E. Kennedy, A. Akcan-Arikan, Y. R. Kang, M. N. Nakamae, K. Hamed, M. M. Khaled, R. Aly Soliman, M. Sherif Mokhtar, G. Seller-Pérez, D. Arias-Verdú, E. Llopar-Valdor, I. De-Diós-Chacón, G. Quesada-García, M. E. Herrera-Gutierrez, R. Hafes, G. Carroll, P. Doherty, C. Wright, I. G. Guerra Vera, M. Ralston, M. L. Gemmell, A. MacKay, E. Black, R. I. Docking, R. Appleton, M. R. Ralston, L. Gemmell, A. Mackay, J. G. Röttgering, P. W. G. Elbers, N. Mejeni, J. Nsiala, A. Kilembe, P. Akilimali, G. Thomas, A. E. Andersson, A. M. Fagerdahl, V. Knudsen, P-INFECT, A. Ben Cheikh, Y. Hamdaoui, A. Guiga, N. Fraj, N. Sma, I. Chouchene, N. Bouafia, A. Amirian, B. Ziaian, C. Fleischmann, D. O. Thomas-Rueddel, A. Schettler, D. Schwarzkopf, A. Stacke, K. Reinhart, A. Martins, P. Sousa, G. Snell, R. Matsa, T. T. S. Paary, A. M. Cavalheiro, L. L. Rocha, C. S. Vallone, A. Tonilo, M. D. S. Lobato, D. T. Malheiro, G. Sussumo, N. M. Lucino, V. D. Rosenthal, A. Sanaei Dashti, A. Yousefipour, J. R. Goodall, M. Williamson, E. Tant, N. Thomas, C. Balci, C. Gonen, E. Haftacı, H. Gurarda, E. Karaca, B. Paldusová, I. Zýková, D. Šímová, S. Houston, L. D’Antona, J. Lloyd, V. Garnelo-Rey, M. Sosic, V. Sotosek-Tokmazic, J. Kuharic, I. Antoncic, S. Dunatov, A. Sustic, C. T. Chong, M. Sim, T. Lyovarin, F. M. Acosta Díaz, S. Narbona Galdó, M. Muñoz Garach, O. Moreno Romero, A. M. Pérez Bailón, A. Carranza Pinel, M. Colmenero, A. Gritsan, A. Gazenkampf, E. Korchagin, N. Dovbish, R. M. Lee, M. P. P. Lim, B. C. L. Lim, J. J. See, R. Assis, F. Filipe, N. Lopes, L. Pessoa, T. Pereira, N. Catorze, M. S. Aydogan, C. Aldasoro, P. Marchio, A. Jorda, M. D. Mauricio, S. Guerra-Ojeda, M. Gimeno-Raga, M. Colque-Cano, A. Bertomeu-Artecero, M. Aldasoro, S. L. Valles, D. Tonon, T. Triglia, J. C. Martin, M. C. Alessi, N. Bruder, P. Garrigue, L. Velly, S. Spina, V. Scaravilli, C. Marzorati, E. Colombo, D. Savo, A. Vargiolu, G. Cavenaghi, G. Citerio, A. H. V. Andrade, P. Bulgarelli, J. A. P. Araujo, V. Gonzalez, V. A. Souza, C. Massant, C. A. C. Abreu Filho, R. A. Morbeck, L. E. Burgo, R. van Groenendael, L. T. van Eijk, G. P. Leijte, B. Koeneman, M. Kox, P. Pickkers, A. García-de la Torre, M. de la Torre-Prados, A. Fernández-Porcel, C. Rueda-Molina, P. Nuevo-Ortega, T. Tsvetanova-Spasova, E. Cámara-Sola, A. García-Alcántara, L. Salido-Díaz, X. Liao, T. Feng, J. Zhang, X. Cao, Q. Wu, Z. Xie, H. Li, Y. Kang, M. S. Winkler, A. Nierhaus, E. Mudersbach, A. Bauer, L. Robbe, C. Zahrte, E. Schwedhelm, S. Kluge, C. Zöllner, E. Mitsi, S. H. Pennington, J. Reine, A. D. Wright, R. Parker, I. D. Welters, J. D. Blakey, G. Rajam, E. W. Ades, D. M. Ferreira, D. Wang, A. Kadioglu, S. B. Gordon, R. Koch, J. Rahamat-Langedoen, J. Schloesser, M. de Jonge, J. Bringue, R. Guillamat-Prats, E. Torrents, M. L. Martinez, M. Camprubí-Rimblas, L. Blanch, S. Y. Park, Y. B. Park, D. K. Song, S. Shrestha, S. H. Park, Y. Koh, M. J. Park, C. W. Hong, O. Lesur, D. Coquerel, X. Sainsily, J. Cote, T. Söllradl, A. Murza, L. Dumont, R. Dumaine, M. Grandbois, P. Sarret, E. Marsault, D. Salvail, M. Auger-Messier, F. Chagnon, Apelin Group, M. P. Lauretta, E. Greco, A. Dyson, S. Preau, M. Ambler, A. Sigurta, S. Saeed, L. Topcu Sarıca, N. Zibandeh, D. Genc, F. Gul, T. Akkoc, E. Kombak, L. Cinel, I. Cinel, S. J. Pollen, N. Arulkumaran, G. Warnes, D. J. Pennington, K. Brohi, M. J. O’Dwyer, H. Y. Kim, S. Na, J. Kim, Y. F. Chang, A. Chao, P. Y. Shih, C. T. Lee, Y. C. Yeh, L. W. Chen, M. Adriaanse, W. Rietdijk, S. Funcke, S. Sauerlaender, B. Saugel, H. Pinnschmidt, D. A. Reuter, R. Nitzschke, S. Perbet, C. Biboulet, A. Lenoire, D. Bourdeaux, B. Pereira, B. Plaud, J. E. Bazin, V. Sautou, A. Mebazaa, J. M. Constantin, M. Legrand, Y. Boyko, P. Jennum, M. Nikolic, H. Oerding, R. Holst, P. Toft, H. K. Nedergaard, T. Haberlandt, S. Park, S. Kim, Y. J. Cho, Y. J. Lim, A. Chan, S. Tang, S. L. Nunes, S. Forsberg, H. Blomqvist, L. Berggren, M. Sörberg, T. Sarapohja, C. J. Wickerts, J. G. M. Hofhuis, L. Rose, B. Blackwood, E. Akerman, J. Mcgaughey, M. Fossum, H. Foss, E. Georgiou, H. J. Graff, M. Kalafati, R. Sperlinga, A. Schafer, A. G. Wojnicka, P. E. Spronk, F. Khalili, R. Afshari, H. Haddad Khodaei, S. Javadpour, P. Petramfar, S. Nasimi, H. Tabei, A. Gunther, J. O. Hansen, P. Sackey, H. Storm, J. Bernhardsson, Ø. Sundin, A. Bjärtå, A. Bienert, P. Smuszkiewicz, P. Wiczling, K. Przybylowski, A. Borsuk, I. Trojanowska, J. Matysiak, Z. Kokot, M. Paterska, E. Grzeskowiak, A. Messina, E. Bonicolini, D. Colombo, G. Moro, S. Romagnoli, A. R. De Gaudio, F. Della Corte, S. M. Romano, J. A. Silversides, E. Major, E. E. Mann, A. J. Ferguson, D. F. Mcauley, J. C. Marshall, J. A. Diaz-Rodriguez, R. Silva-Medina, E. Gomez-Sandoval, N. Gomez-Gonzalez, R. Soriano-Orozco, P. L. Gonzalez-Carrillo, M. Hernández-Flores, K. Pilarczyk, J. Lubarksi, D. Wendt, F. Dusse, J. Günter, B. Huschens, E. Demircioglu, H. Jakob, A. Palmaccio, A. M. Dell’Anna, D. L. Grieco, F. Torrini, C. Iaquaniello, F. Bongiovanni, M. Antonelli, L. Toscani, D. Antonakaki, D. Bastoni, M. Jozwiak, F. Depret, J. L. Teboul, J. Alphonsine, C. Lai, C. Richard, X. Monnet, G. Demeter, I. Kertmegi, A. Hasanin, A. Lotfy, A. El-adawy, H. Nassar, S. Mahmoud, A. Abougabal, A. Mukhtar, F. Quinty, S. Habchi, A. Luzi, E. Antok, G. Hernandez, B. Lara, L. Enberg, M. Ortega, P. Leon, C. Kripper, P. Aguilera, E. Kattan, M. Lehmann, S. Sakka, B. Bein, R. M. Schmid, J. Preti, J. Creteur, A. Herpain, J. Marc, F. Trojette, S. Bar, L. Kontar, D. Titeca, J. Richecoeur, B. Gelee, N. Verrier, R. Mercier, E. Lorne, J. Maizel, M. Slama, M. E. Abdelfattah, A. Eladawy, M. A. Ali Elsayed, A. Pedraza Montenegro, E. Monares Zepeda, J. Franco Granillo, J. S. Aguirre Sánchez, G. Camarena Alejo, A. Rugerio Cabrera, A. A. Tanaka Montoya, C. Lee, F. Hatib, M. Cannesson, P. Theerawit, T. Morasert, Y. Sutherasan, G. Zani, S. Mescolini, M. Diamanti, R. Righetti, A. Scaramuzza, M. Papetti, M. Terenzoni, C. Gecele, M. Fusari, K. A. Hakim, A. Chaari, M. Ismail, A. H. Elsaka, T. M. Mahmoud, K. Bousselmi, V. Kauts, W. F. Casey, S. D. Hutchings, D. Naumann, J. Wendon, S. Watts, E. Kirkman, Z. Jian, S. Buddi, J. Settels, P. Bertini, F. Guarracino, C. Trepte, P. Richter, S. A. Haas, V. Eichhorn, J. C. Kubitz, M. S. Soliman, W. I. Hamimy, A. Z. Fouad, A. M. Mukhtar, M. Charlton, L. Tonks, L. Mclelland, T. J. Coats, J. P. Thompson, M. R. Sims, D. Williams, D. Z. Roushdy, R. A. Soliman, R. A. Nahas, M. Y. Arafa, W. T. Hung, C. C. Chiang, W. C. Huang, K. C. Lin, S. C. Lin, C. C. Cheng, P. L. Kang, S. R. Wann, G. Y. Mar, C. P. Liu, M. Lopez Carranza, H. Sancho Fernandez, J. A. Sanchez Roman, F. Lucena, A. Campanario Garcia, A. Loza Vazquez, A. Lesmes Serrano, ARIAM-SEMICYUC Registry Investigators, L. Sayagues Moreira, R. Vidal-Perez, U. Anido Herranz, J. M. Garcia Acuna, C. Pena Gil, J. L. Garcia Allut, P. Rascado Sedes, C. Martin Lopez, E. Saborido Paz, C. Galban Rodriguez, J. R. Gonzalez-Juanatey, A. Vallejo-Baez, M. V. de la Torre-Prados, ARIAM Group, R. Marharaj, K. Gervasio, M. Bottiroli, M. Mondino, D. De Caria, A. Calini, E. Montrasio, F. Milazzo, M. P. Gagliardone, A. Vallejo-Báez, ARIAM group, U. Anido, M. Cheikh-Bouhlel, M. P. R. D. L. Dela Cruz, J. M. Bernardo, F. Galfo, A. Marino, C. C. Chao, P. Hou, C. C. Hung, C. H. Chiang, Y. J. Liou, S. M. Hung, Y. S. Lin, F. Y. Kuo, K. R. Chiou, C. J. Chen, L. S. Yan, C. Y. Liu, H. H. Wang, H. L. Chen, C. K. Ho, S. Grewal, S. Gopal, C. Corbett, A. Wilson, J. Capps, W. Ayoub, A. Lomas, S. Ghani, J. Moore, D. Atkinson, M. Sharman, W. Swinnen, J. Pauwels, K. Mignolet, E. Pannier, A. Koch, T. Sarens, W. Temmerman, A. M. Elmenshawy, A. M. Fayed, M. Elboriuny, E. Hamdy, E. Zakaria, A. C. Falk, A. Petosic, K. Olafsen, H. Wøien, H. Flaatten, K. Sunde, J. J. Cáceres Agra, J. L. Santana Cabrera, J. D. Martín Santana, L. Melián Alzola, H. Rodríguez Pérez, T. Castro Pires, H. Calderón, A. Pereira, S. Castro, C. Granja, I. Norkiene, I. Urbanaviciute, G. Kezyte, D. Ringaitiene, T. Jovaisa, G. Vogel, U. B. Johansson, A. Sandgren, C. Svensen, E. Joelsson-Alm, M. A. Leite, L. D. Murbach, E. F. Osaku, C. R. L. M. Costa, M. Pelenz, N. M. Neitzke, M. M. Moraes, J. L. Jaskowiak, M. M. M. Silva, R. S. Zaponi, L. R. L. Abentroth, S. M. Ogasawara, A. C. Jorge, P. A. D. Duarte, J. Barreto, S. T. Duarte, S. Taba, D. Miglioranza, D. P. Gund, C. F. Lordani, H. Vollmer, M. Gager, C. Waldmann, A. T. Mazzeo, R. Tesio, C. Filippini, M. E. Vallero, C. Giolitti, S. Caccia, M. Medugno, T. Tenaglia, R. Rosato, I. Mastromauro, L. Brazzi, P. P. Terragni, R. Urbino, V. Fanelli, V. M. Ranieri, L. Mascia, J. Ballantyne, L. Paton, P. Perez-Teran, O. Roca, J. C. Ruiz-Rodriguez, A. Zapatero, J. Serra, S. Bianzina, P. Cornara, G. Rodi, G. Tavazzi, M. Pozzi, G. A. Iotti, F. Mojoli, A. Braschi, A. Vishnu, D. Buche, R. Pande, D. L. J. Moolenaar, F. Bakhshi-Raiez, D. A. Dongelmans, N. F. de Keizer, D. W. de Lange, I. Fuentes Fernández, D. Martínez Baño, J. L. Buendía Moreno, R. Jara Rubio, J. Scott, D. Phelan, D. Morely, J. O’Flynn, P. Stapleton, M. Lynch, B. Marsh, E. Carton, C. O’Loughlin, K. C. Cheng, M. I. Sung, M. O. Elghonemi, M. H. Saleh, T. S. Meyhoff, M. Krag, P. B. Hjortrup, M. H. Møller, T. Öhman, T. Sigmundsson, E. Redondo, M. Hallbäck, F. Suarez-Sipmann, H. Björne, C. Hällsjö Sander, KARISMA, D. Chiumello, C. Chiurazzi, M. Brioni, I. Algieri, M. Guanziroli, G. Vergani, T. Tonetti, I. Tomic, A. Colombo, F. Crimella, E. Carlesso, V. Gasparovic, R. El-Sherif, M. Abd Al-Basser, A. Raafat, A. El-Sherif, L. R. A. Schouten, O. L. Cremer, D. S. Y. Ong, G. Amoruso, G. Cinnella, L. D. J. Bos, P. Schmidle, M. Findeisen, P. Hoppmann, J. Jaitner, F. Brettner, T. Lahmer, EXODUS-investigators, G. Rajagopalan, V. Bansal, R. Frank, R. Hinds, J. Levitt, United States Critical Illness and Injury Trials Group/LIPS-B investigators, S. Siddiqui, SICM NICER Group, J. P. Gilbert, K. Sim, C. H. Wang, I. J. Li, W. R. Tang, P. Persona, A. De Cassai, M. Franco, A. Goffi, B. Llorente Ruiz, J. Lujan Varas, R. Molina Montero, C. Pintado Delgado, O. Navarrete, M. Vazquez Mezquita, E. Alonso Peces, M. A. M. Nakamura, L. A. Hajjar, F. R. B. G. Galas, T. A. Ortiz, M. B. P. Amato, L. Bitker, N. Costes, D. Le Bars, F. Lavenne, D. Mojgan, J. C. Richard, D. Massari, M. Gotti, P. Cadringher, A. Zerman, M. Türkoğlu, G. Arık, F. Yıldırım, Z. Güllü, I. Kara, N. Boyacı, B. Basarık Aydoğan, Ü. Gaygısız, K. Gönderen, G. Aygencel, M. Aydoğdu, Z. Ülger, G. Gürsel, J. Riera, C. Maldonado Toral, C. Mazo, M. Martínez, J. Baldirà, L. Lagunes, A. Roman, M. Deu, J. Rello, D. J. Levine, R. M. Mohus, Å. Askim, J. Paulsen, A. Mehl, A. T. Dewan, J. K. Damås, E. Solligård, B. O. Åsvold, Mid-Norway Sepsis Research Center, A. DeWan, O. Aktepe, A. Kara, H. Yeter, A. Topeli, M. Norrenberg, M. Devroey, H. Khader, J. C. Preiser, Z. Tang, C. Qiu, L. Tong, C. Cai, O. Apostolopoulou, J. Y. Moon, M. R. Park, I. S. Kwon, G. R. Chon, J. Y. Ahn, S. J. Kwon, Y. J. Chang, J. Y. Lee, S. Y. Yoon, J. W. Lee, The Korean Chungcheong Critical Care Research Group, M. Kostalas, J. Mckinlay, G. Kooner, G. Dudas, A. Horton, C. Kerr, N. Karanjia, B. Creagh-Brown, N. D. Altintas, S. Izdes, O. Keremoglu, A. Alkan, S. Neselioglu, O. Erel, N. Tardif, T. Gustafsson, K. N. MacEachern, M. Traille, I. Bromberg, S. E. Lapinsky, M. J. Moore, J. L. García-Garmendia, F. Villarrasa-Clemente, F. Maroto-Monserrat, O. Rufo-Tejeiro, V. Jorge-Amigo, M. Sánchez-Santamaría, C. Colón-Pallarés, A. Barrero-Almodóvar, S. Gallego-Lara, C. T. Anthon, R. B. Müller, N. Haase, K. Møller, J. Wetterslev, M. Nakanishi, A. Kuriyama, T. Fukuoka, M. A. Abd el Halim, M. H. Elsaid hafez, A. M. Moktar, H. M. Elazizy, K. Abdel Hakim, M. Elbahr, T. Mahmoud, E. Khalil, W. Casey, S. H. Zaky, A. Rizk, R. Ahmed, G. A. Ospina-Tascón, A. F. Garcia Marin, G. J. Echeverry, W. F. Bermudez, H. J. Madriñan-Navia, J. D. Valencia, E. Quiñonez, A. Marulanda, C. A. Arango-Dávila, A. Bruhn, D. De Backer, D. Orbegozo Cortes, F. Su, J. L. Vincent, L. Tullo, L. Mirabella, P. Di Molfetta, M. Dambrosio, C. Villavicencio Lujan, J. Leache irigoyen, M. Cartanya ferré, R. Carbonell García, M. Ahmed, M. El Ayashi, E. Ayman, M. Salem, S. Fathy, A. Zaghlol, M. F. Aguilar Arzapalo, Å. Valsø, T. Rustøen, I. Schou-Bredal, L. Skogstad, K. Tøien, C. Padilla, Y. Palmeiro, W. Egbaria, R. Kigli, B. Maertens, K. Blot, S. Blot, E. Santana-Santos, E. R. dos Santos, R. E. D. L. Ferretti-Rebustini, R. D. C. C. D. O. dos Santos, R. G. S. Verardino, L. A. Bortolotto, A. M. Doyle, I. Naldrett, J. Tillman, S. Price, P. Pearson, J. Greaves, D. Goodall, A. Berry, A. Richardson, G. O. Odundo, P. Omengo, P. Obonyo, N. M. Chanzu, R. Kleinpell, S. J. Sarris, P. Nedved, M. Heitschmidt, H. Ben-Ghezala, S. Snouda, S. Djobbi, N. K. J. Adhikari, D. Leasa, D. Fergusson, D. A. Mckim, J. Weblin, D. McWilliams, F. Doesburg, F. Cnossen, W. Dieperink, W. Bult, M. W. N. Nijsten, G. A. Galvez-Blanco, C. I. Olvera Guzman, J. Santos Stroud, R. Thomson, M. Llaurado-Serra, A. Lobo-Civico, M. Pi-Guerrero, I. Blanco-Sanchez, A. Piñol-Tena, C. Paños-Espinosa, Y. Alabart-Segura, B. Coloma-Gomez, A. Fernandez-Blanco, F. Braga-Dias, M. Treso-Geira, A. Valeiras-Valero, L. Martinez-Reyes, A. Sandiumenge, M. F. Jimenez-Herrera, CAPCRI Study, R. Prada, P. Juárez, R. Argandoña, J. J. Díaz, C. Sánchez Ramirez, P. Saavedra, S. Ruiz Santana, O. Obukhova, S. Kashiya, I. A. Kurmukov, A. M. Pronina, P. Simeone, L. Puybasset, G. Auzias, O. Coulon, B. Lesimple, G. Torkomian, A. Bartkowska-Sniatkowska, O. Szerkus, D. Siluk, J. Bartkowiak-Wieczorek, J. Rosada-Kurasinska, J. Warzybok, R. Kaliszan, C. Hernandez Caballero, S. Roberts, G. Isgro, D. Hall, G. Guillaume, O. Passouant, F. Dumas, W. Bougouin, B. Champigneulle, M. Arnaout, J. Chelly, J. D. Chiche, O. Varenne, J. P. Mira, E. Marijon, A. Cariou, M. Beerepoot, H. R. Touw, K. Parlevliet, C. Boer, P. W. Elbers, Á. J. Roldán Reina, Y. Corcia Palomo, R. Martín Bermúdez, L. Martín Villén, I. Palacios García, J. R. Naranjo Izurieta, J. B. Pérez Bernal, F. J. Jiménez Jiménez, Cardiac Arrest Group HUVR, F. Cota-Delgado, T. Kaneko, H. Tanaka, M. Kamikawa, R. Karashima, S. Iwashita, H. Irie, S. Kasaoka, O. Arola, R. Laitio, A. Saraste, J. Airaksinen, M. Pietilä, M. Hynninen, J. Wennervirta, M. Bäcklund, E. Ylikoski, P. Silvasti, E. Nukarinen, J. Grönlund, V. P. Harjola, J. Niiranen, K. Korpi, M. Varpula, R. O. Roine, T. Laitio, for the Xe-HYPOTHECA study group, S. Salah, B. G. Hassen, A. Mohamed Fehmi, Y. C. Hsu, J. Barea-Mendoza, C. García-Fuentes, M. Castillo-Jaramillo, H. Dominguez-Aguado, R. Viejo-Moreno, L. Terceros-Almanza, S. Bermejo Aznárez, C. Mudarra-Reche, W. Xu, M. Chico-Fernández, J. C. Montejo-González, K. Crewdson, M. Thomas, M. Merghani, L. Fenner, P. Morgan, D. Lockey, E. J. van Lieshout, B. Oomen, J. M. Binnekade, R. J. de Haan, N. P. Juffermans, M. B. Vroom, R. Algarte, L. Martínez, B. Sánchez, I. Romero, F. Martínez, S. Quintana, J. Trenado, O. Sheikh, D. Pogson, R. Clinton, F. Riccio, A. Arthur, L. Young, A. Sinclair, D. Markopoulou, K. Venetsanou, L. Filippou, E. Salla, S. Stratouli, I. Alamanos, A. H. Guirgis, R. Gutiérrez Rodriguez, M. J. Furones Lorente, I. Macias Guarasa, A. Ukere, S. Meisner, G. Greiwe, B. Opitz, D. Benten, B. Nashan, L. Fischer, C. J. C. Trepte, C. R. Behem, B. Ana, A. Vazir, D. Gibson, M. R. Hadavi, M. Riahi alam, M. R. Sasani, N. Parenti, F. Agrusta, C. Palazzi, B. Pifferi, R. Sganzerla, F. Tagliazucchi, A. Luciani, M. Möller, J. Müller-Engelmann, G. Montag, P. Adams, C. Lange, J. Neuzner, R. Gradaus, K. H. Wodack, F. Thürk, A. D. Waldmann, M. F. Grässler, S. Nishimoto, S. H. Böhm, E. Kaniusas, C. J. Trepte, M. Wallin, F. Suarez Sipman, A. Oldner, L. Colinas, R. Vicho, M. Serna, R. Cuena, A. Canabal, ECOCRITIC group, M. Etman, M. El Bahr, A. El Sakka, A. Arali, O. Bond, P. De Santis, E. Iesu, F. Franchi, S. Scolletta, F. S. Taccone, Z. Marutyan, L. Hamidova, A. Shakotko, V. Movsisyan, I. Uysupova, A. Evdokimov, S. Petrikov, F. J. Redondo Calvo, N. Bejarano, V. Baladron, R. Villazala, J. Redondo, D. Padilla, P. Villarejo, C. Gomez-Gonzalez, S. Mas-Font, A. Puppo-Moreno, M. Herrera-Gutierrez, M. Garcia-Garcia, S. Aldunate-Calvo, NEFROCON Investigators, E. P. Plata-Menchaca, X. L. Pérez-Fernández, M. Estruch, A. Betbese-Roig, P. Cárdenas Campos, M. Rojas Lora, N. D. Toapanta Gaibor, R. S. Contreras Medina, V. D. Gumucio Sanguino, E. J. Casanova, J. Sabater Riera, SIRAKI group, K. Kritmetapak, S. Peerapornratana, P. Kittiskulnam, T. Dissayabutra, P. Susantithapong, K. Praditpornsilpa, K. Tungsanga, S. Eiam-Ong, T. Winkelmann, T. Busch, J. Meixensberger, S. Bercker, E. M. Flores Cabeza, M. Sánchez Sánchez, N. Cáceres Giménez, C. Gutierrez Melón, E. Herrero de Lucas, P. Millán Estañ, M. Hernández Bernal, A. Garcia de Lorenzo y Mateos, P. A. C. Specht, M. Balik, M. Zakharchenko, F. Los, H. Brodska, C. de Tymowski, P. Augustin, M. Desmard, P. Montravers, S. N. Stapel, R. de Boer, H. M. Oudemans, A. Hollinger, T. Schweingruber, F. Jockers, M. Dickenmann, M. Siegemund, Clinical Intensive Care Research Basel, N. Runciman, L. Alban, C. Turrini, T. Sasso, T. Langer, P. Taccone, C. Marenghi, G. Grasselli, P. Wibart, T. Reginault, M. Garcia, B. Barbrel, A. Benard, C. Bader, F. Vargas, H. N. Bui, G. Hilbert, J. M. Serrano Simón, P. Carmona Sánchez, F. Ruiz Ferrón, M. García de Acilu, J. Marin, V. Antonia, L. Ruano, M. Monica, G. Hong, D. H. Kim, Y. S. Kim, J. S. Park, Y. K. Jee, Z. Yu xiang, W. Jia-xing, W. Xiao dan, N. Wen long, W. Yu, Z. Yan, X. Cheng, T. Kobayashi, Y. Onodera, R. Akimoto, A. Sugiura, H. Suzuki, M. Iwabuchi, M. Nakane, K. Kawamae, P. Carmona Sanchez, M. D. Bautista Rodriguez, M. Rodriguez Delgado, V. Martínez de Pinillos Sánchez, A. Mula Gómez, P. Beuret, C. Fortes, M. Lauer, M. Reboul, J. C. Chakarian, X. Fabre, B. Philippon-Jouve, S. Devillez, M. Clerc, N. Rittayamai, M. Sklar, M. Dres, M. Rauseo, C. Campbell, B. West, D. E. Tullis, M. Okada, N. Ahmad, M. Wood, A. Glossop, J. Higuera Lucas, A. Blandino Ortiz, D. Cabestrero Alonso, R. De Pablo Sánchez, L. Rey González, R. Costa, G. Spinazzola, A. Pizza, G. Ferrone, M. Rossi, G. Conti, H. Ribeiro, J. Alves, M. Sousa, P. Reis, C. S. Socolovsky, R. P. Cauley, J. E. Frankel, A. L. Beam, K. O. Olaniran, F. K. Gibbons, K. B. Christopher, J. Pennington, P. Zolfaghari, H. S. King, H. H. Y. Kong, H. P. Shum, W. W. Yan, C. Kaymak, N. Okumus, A. Sari, B. Erdogdu, S. Aksun, H. Basar, A. Ozcan, N. Ozcan, D. Oztuna, J. A. Malmgren, S. Lundin, K. Torén, M. Eckerström, A. Wallin, A. C. Waldenström, for the Section on Ethics of the ESICM, F. C. Riccio, A. C. P. Antonio, A. F. Leivas, F. Kenji, E. James, S. Jonnada, C. S. Gerrard, N. Jones, J. D. Salciccioli, D. C. Marshall, M. Komorowski, A. Hartley, M. C. Sykes, R. Goodson, J. Shalhoub, J. R. Fernández Villanueva, R. Fernández Garda, A. M. López Lago, E. Rodríguez Ruiz, R. Hernández Vaquero, C. Galbán Rodríguez, E. Varo Pérez, C. Hilasque, I. Oliva, G. Sirgo, M. C. Martin, M. Olona, M. C. Gilavert, M. Bodí, C. Ebm, G. Aggarwal, S. Huddart, N. Quiney, S. M. Fernandes, J. Santos Silva, J. Gouveia, D. Silva, R. Marques, H. Bento, A. Alvarez, Z. Costa Silva, D. Díaz Diaz, M. Villanova Martínez, E. Palencia Herrejon, A. Martinez de la Gandara, G. Gonzalo, M. A. Lopez, P. Ruíz de Gopegui Miguelena, C. I. Bernal Matilla, P. Sánchez Chueca, M. D. C. Rodríguez Longares, R. Ramos Abril, A. L. Ruíz Aguilar, R. Garrido López de Murillas, R. Fernández Fernández, P. Morales Laborías, M. A. Díaz Castellanos, M. E. Morales Laborías, J. Park, S. Woo, T. West, E. Powell, A. Rimmer, C. Orford, J. Williams, P. Ruiz de Gopegui Miguelena, R. S. Bourne, R. Shulman, M. Tomlin, G. H. Mills, M. Borthwick, W. Berry, D. García Huertas, F. Manzano, F. Villagrán-Ramírez, A. Ruiz-Perea, C. Rodríguez-Mejías, F. Santiago-Ruiz, M. Colmenero-Ruiz, C. König, B. Matt, A. Kortgen, C. S. Hartog, A. Wong, C. Balan, G. Barker, S. Tachaboon, J. Paratz, G. Kayambu, R. Boots, R. Vlasenko, E. Gromova, S. Loginov, M. Kiselevskiy, Y. Dolgikova, K. B. Tang, C. M. Chau, K. N. Lam, E. Gil, G. Y. Suh, C. M. Park, C. R. Chung, C. H. Lai, Y. J. Cheng, V. Colella, N. Zarrillo, M. D’Amico, F. Forfori, B. Pezza, T. Laddomada, V. Beltramelli, M. L. Pizzaballa, A. Doronzio, B. Balicco, D. Kiers, W. van der Heijden, J. Gerretsen, Q. de Mast, S. el Messaoudi, G. Rongen, M. Gomes, N. P. Riksen, Y. Kashiwagi, K. Hayashi, Y. Inagaki, S. Fujita, A. Blet, M. Sadoune, J. Lemarié, N. Bihry, R. Bern, E. Polidano, R. Merval, J. M. Launay, B. Lévy, J. L. Samuel, J. Hartmann, S. Harm, and V. Weber
Subjects: Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
Published: 2016
Full Text: View/download PDF

24. Treatment of Surgical Scars With Combination Pulsed Dye and Fractional Nonablative Laser

Author: Bianca Y, Kang, Sarah A, Ibrahim, Alexandra, Weil, Kelly A, Reynolds, Tyler, Johnson, Sarah, Wilson, Ming H, Lee, John Y S, Kim, McKenzie A, Dirr, Emily, Poon, and Murad, Alam
Subjects: Adult, Cicatrix, Wound Healing, Treatment Outcome, Erythema, Humans, Lasers, Dye, Surgery
Abstract: To assess the effectiveness and safety of combined pulsed-dye laser (PDL) and NAFL for treatment of surgical scars.PDL and NAFL have not been compared to healing by time alone.Randomized controlled, single-blinded clinical trial at an urban, university hospital. Healthy adults' status post skin surgery with primary closure were randomized to either 3 sessions of combination PDL and NAFL every 2 to 8 weeks, or control of no treatment. At baseline and 36-week follow-up, Patient and observer Scar Assessment Scale and Scar Cosmesis Assessment and Rating were completed by participants and blinded physicians. The primary outcome was scar improvement, as measured by the score difference over time.Of 76 participants, 52 completed the study (July 2017 to June 2019). No severe adverse events were reported. Patient and observer Scar Assessment Scale assessments demonstrated improvement in total score in the laser group compared to controls, as reported by patients [mean difference (standard deviation), laser: 12.86 (6.91) vs control: 7.25 (6.34); P = 0.004] and blinded physicians [18.32 (8.69) vs 13.08 (9.63); P = 0.044]. Patients observed a greater improvement in scar thickness [3.68 (2.04) vs 1.88 (1.85); P = 0.002] and stiffness [3.57 (2.78) vs 1.50 (2.11); P = 0.004] with lasers, and physicians reported greater improvement in vascularity [3.71 (1.98) vs 1.71 (1.52); P = 0.0002]. The live Scar Cosmesis Assessment and Rating subscore for erythema improved significantly with lasers [1.04 (0.79) vs 0.42 (0.50); P = 0.001].Combined PDL and NAFL resulted in scar improvement. Scar thickness, stiffness, and erythema were improved.ClinicalTrials.gov (NCT03057964).
Published: 2022

25. Quantum Mechanics of Moving Bound States

Author: Y. S. Kim
Published: 2022

26. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy

Author: Yi You, Yu Tian, Zhaogang Yang, Junfeng Shi, Kwang Joo Kwak, Yuhao Tong, Andreanne Poppy Estania, Jianhong Cao, Wei-Hsiang Hsu, Yutong Liu, Chi-Ling Chiang, Benjamin R. Schrank, Kristin Huntoon, DaeYong Lee, Ziwei Li, Yarong Zhao, Huan Zhang, Thomas D. Gallup, JongHoon Ha, Shiyan Dong, Xuefeng Li, Yifan Wang, Wen-Jing Lu, Eman Bahrani, Ly James Lee, Lesheng Teng, Wen Jiang, Feng Lan, Betty Y. S. Kim, and Andrew S. Lee
Subjects: Biomedical Engineering, Medicine (miscellaneous), Bioengineering, Computer Science Applications, Biotechnology
Published: 2023

27. EXPERIMENTAL STUDY ON R-407C EVAPORATION HEAT TRANSFER CHARACTERISTICS IN PLATE AND SHELL HEAT EXCHANGER

Author: J. H. Park and Y. S. Kim
Published: 2023

28. Changes in outcomes and factors associated with survival in melanoma patients with brain metastases

Author: Merve Hasanov, Denái R Milton, Alicia Bea Davies, Elizabeth Sirmans, Chantal Saberian, Eliza L Posada, Sylvia Opusunju, Jeffrey E Gershenwald, Carlos A Torres-Cabala, Elizabeth M Burton, Rivka R Colen, Jason T Huse, Isabella C Glitza Oliva, Caroline Chung, Mary Frances McAleer, Susan L McGovern, Debra N Yeboa, Betty Y S Kim, Sujit S Prabhu, Ian E McCutcheon, Jeffrey S Weinberg, Frederick F Lang, Hussein A Tawbi, Jing Li, Lauren E Haydu, Michael A Davies, and Sherise D Ferguson
Subjects: Cancer Research, Oncology, Neurology (clinical)
Abstract: Background Treatment options for patients with melanoma brain metastasis (MBM) have changed significantly in the last decade. Few studies have evaluated changes in outcomes and factors associated with survival in MBM patients over time. The aim of this study is to evaluate changes in clinical features and overall survival (OS) for MBM patients. Methods Patients diagnosed with MBMs from 1/1/2009 to 12/31/2013 (Prior Era; PE) and 1/1/2014 to 12/31/2018 (Current Era; CE) at The University of Texas MD Anderson Cancer Center were included in this retrospective analysis. The primary outcome measure was OS. Log-rank test assessed differences between groups; multivariable analyses were performed with Cox proportional hazards models and recursive partitioning analysis (RPA). Results A total of 791 MBM patients (PE, n = 332; CE, n = 459) were included in analysis. Median OS from MBM diagnosis was 10.3 months (95% CI, 8.9–12.4) and improved in the CE vs PE (14.4 vs 10.3 months, P Conclusions OS and factors associated with OS have changed for MBM patients. This information can inform contemporary patient management and clinical investigations.
Published: 2022

29. Association of circulating markers with cognitive decline after radiation therapy for brain metastasis

Author: Kristin Huntoon, S Keith Anderson, Karla V Ballman, Erin Twohy, Katharine Dooley, Wen Jiang, Yi An, Jing Li, Christina von Roemeling, Yaqing Qie, Owen A Ross, Jane H Cerhan, Anthony C Whitton, Jeffrey N Greenspoon, Ian F Parney, Jonathan B Ashman, Jean-Paul Bahary, Constantinos Hadjipanayis, James J Urbanic, Elana Farace, Deepak Khuntia, Nadia N Laack, Paul D Brown, David Roberge, and Betty Y S Kim
Subjects: Cancer Research, Oncology, Neurology (clinical)
Abstract: Background A recent phase III trial (NCT01372774) comparing use of stereotactic radiosurgery [SRS] versus whole-brain radiation therapy [WBRT] after surgical resection of a single brain metastasis revealed that declines in cognitive function were more common with WBRT than with SRS. A secondary endpoint in that trial, and the primary objective in this secondary analysis, was to identify baseline biomarkers associated with cognitive impairment after either form of radiotherapy for brain metastasis. Here we report our findings on APOE genotype and serum levels of associated proteins and their association with radiation-induced neurocognitive decline. Methods In this retrospective analysis of prospectively collected samples from a completed randomized clinical trial, patients provided blood samples every 3 months that were tested by genotyping and enzyme-linked immunosorbent assay, and results were analyzed in association with cognitive impairment. Results The APOE genotype was not associated with neurocognitive impairment at 3 months. However, low serum levels of ApoJ, ApoE, or ApoA protein (all P < .01) and higher amyloid beta (Aβ 1–42) levels (P = .048) at baseline indicated a greater likelihood of neurocognitive decline at 3 months after SRS, whereas lower ApoJ levels were associated with decline after WBRT (P = .014). Conclusions Patients with these pretreatment serum markers should be counseled about radiation-related neurocognitive decline.
Published: 2022

30. Breast Implants and Immune Modulation: Does Foreign Body-Induced Inflammation Promote Immunosurveillance of Breast Tumor Antigen?

Author: Megan Fracol, MD, Nikita Shah, BS, David Dolivo, PhD, Seok-Jong Hong, PhD, Lexa Giragosian, BS, Robert D. Galiano, MD, Thomas A. Mustoe, MD, FACS, and John Y. S. Kim, MD
Subjects: Surgery, RD1-811
Published: 2020
Full Text: View/download PDF

31. Sarcopenia is associated with cardiovascular risk in patients with COPD, independent of adiposity

Author: J Y Jung, A Y Leem, Y S Kim, K S Chung, M S Park, S U Kim, Y A Kang, and Y Park
Published: 2022

32. Appropriate sites for active surveillance of carbapenemase-producing Enterobacterales

Author: J H, Park, H-S, Choi, H, Yang, H-J, Lee, S H, Kwak, E O, Kim, Y P, Chong, S-H, Choi, S-O, Lee, Y S, Kim, H, Sung, M-N, Kim, S-H, Kim, and J, Jung
Subjects: Microbiology (medical), Infectious Diseases, Bacterial Proteins, Enterobacteriaceae Infections, Humans, General Medicine, Watchful Waiting, beta-Lactamases, Anti-Bacterial Agents
Published: 2022

33. Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations

Author: David Sands, Shahid Lambe, Jehonathan H. Pinthus, John Y. S. Kim, Pablo E. Serrano, Harkanwal Randhawa, and Marco Puglia
Subjects: medicine.medical_specialty, Bladder cancer, Cirrhosis, business.industry, Urology, Muscle invasive, medicine.disease, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030211 gastroenterology & hepatology, In patient, business
Abstract: The incidence of liver cirrhosis is increasing worldwide. Patients with cirrhosis are generally at a higher risk of harbouring hepatic and non-hepatic malignancies, including bladder cancer, likely due to the presence of related risk factors such as smoking. Cirrhosis can complicate both the operative and non-surgical management of bladder cancer. For example, cirrhotic patients undergoing abdominal surgery generally demonstrate worse postoperative outcomes, and chemotherapy in patients with cirrhosis often requires dose reduction due to its direct hepatotoxic effects and reduced hepatic clearance. Multiple other considerations in the peri-operative management for cirrhosis patients with muscle-invasive bladder cancer must be taken into account to optimize outcomes in these patients. Unfortunately, the current literature specifically related to the treatment of cirrhotic bladder cancer patients remains sparse. We aim to review the literature on treatment considerations for this patient population with respect to perioperative, surgical, and adjuvant management.
Published: 2021

34. Identification of the Side Population Associated with ATP-Binding Cassette Transporters Activity Using Imaging Flow Cytometry

Author: A. M. Gisina, Y. S. Kim, K. N. Yarygin, and A. Yu. Lupatov
Subjects: Clinical Biochemistry, Molecular Medicine, Biochemistry
Published: 2021

35. Vision-Based Self-localization of Autonomous Guided Vehicle Using Landmarks of Colored Pentagons.

Author: Y. S. Kim, J. C. Kim, Eun-Jong Park, and Joonwhoan Lee
Published: 2006
Full Text: View/download PDF

36. The Palpable Nodule after Autologous Fat Grafting: Distinguishing Benign versus Malignant Lesions in Breast Reconstruction

Author: Megan Fracol, Sophia Allison, Yuyang Chu, Yufan Yan, Rachita Sood, Lauren N. Feld, and John Y. S. Kim
Subjects: Adipose Tissue, Mammaplasty, Humans, Surgery, Transplantation, Autologous, Follow-Up Studies, Retrospective Studies
Abstract: Nodule formation after autologous fat grafting to the breast is the most common complication. In the reconstructive population, this generates significant patient anxiety and presents a diagnostic challenge. The authors characterized palpable nodule occurrence after autologous fat grafting in breast reconstruction and compared benign versus malignant nodule characteristics.Chart review of the senior author's experience with breast fat grafting was performed. Data extracted included demographics, intraoperative details, nodule data, radiographic characteristics, and biopsy results. Logistic regression identified risk factors for nodule formation. Unpaired t tests and Fisher exact tests compared characteristics of benign versus malignant nodules.In total, 775 breasts were identified that underwent 1158 fat grafting procedures, of which 67 (8.6 percent) developed palpable nodules. Sonographic characterization of nodules included presumed fat necrosis (38.2 percent), benign lesions (27.6 percent), presumed oil cysts (17.1 percent), indeterminate (8.9 percent), and concerning for malignancy (8.1 percent). Lesions concerning for malignancy were more often irregular (10.0 percent versus 0 to 2.9 percent of benign nodules) and more often larger than 0.8 cm in greatest dimension (80 percent versus 42.9 to 61.8 percent of benign nodules). Six patients developed a palpable local recurrence. Malignant nodules tended to be larger (1.45 cm versus 0.70 cm; p = 0.03), were more often vascular (50 percent versus 3.8 percent; p = 0.03), and tended to occur later (17.5 months versus 10.0 months; p = 0.60). Benign nodules occurred in the setting of larger fat graft volumes (64.2 cc versus 40.0 cc; p = 0.008).This study provides the first comparison of radiographic and clinical characteristics between benign and malignant palpable nodules after autologous fat grafting in breast reconstruction.Risk, III.
Published: 2022

37. Peripheral apoE4 enhances Alzheimer’s pathology and impairs cognition by compromising cerebrovascular function

Author: Chia-Chen Liu, Jing Zhao, Yuan Fu, Yasuteru Inoue, Yingxue Ren, Yuanxin Chen, Sydney V. Doss, Francis Shue, Suren Jeevaratnam, Ligia Bastea, Na Wang, Yuka A. Martens, Wenhui Qiao, Minghui Wang, Na Zhao, Lin Jia, Yu Yamazaki, Akari Yamazaki, Cassandra L. Rosenberg, Zhen Wang, Dehui Kong, Zonghua Li, Lindsey A. Kuchenbecker, Zachary A. Trottier, Lindsey Felton, Justin Rogers, Zachary S. Quicksall, Cynthia Linares, Joshua Knight, Yixing Chen, Aishe Kurti, Takahisa Kanekiyo, John D. Fryer, Yan W. Asmann, Peter Storz, Xusheng Wang, Junmin Peng, Bin Zhang, Betty Y. S. Kim, and Guojun Bu
Subjects: General Neuroscience, Apolipoprotein E4, Induced Pluripotent Stem Cells, Apolipoprotein E3, Brain, Mice, Transgenic, Article, Mice, Apolipoproteins E, Cognition, Alzheimer Disease, Animals, Humans, Protein Isoforms
Abstract: The ε4 allele of the apolipoprotein E (APOE) gene, a genetic risk factor for Alzheimer's disease, is abundantly expressed in both the brain and periphery. Here, we present evidence that peripheral apoE isoforms, separated from those in the brain by the blood-brain barrier, differentially impact Alzheimer's disease pathogenesis and cognition. To evaluate the function of peripheral apoE, we developed conditional mouse models expressing human APOE3 or APOE4 in the liver with no detectable apoE in the brain. Liver-expressed apoE4 compromised synaptic plasticity and cognition by impairing cerebrovascular functions. Plasma proteome profiling revealed apoE isoform-dependent functional pathways highlighting cell adhesion, lipoprotein metabolism and complement activation. ApoE3 plasma from young mice improved cognition and reduced vessel-associated gliosis when transfused into aged mice, whereas apoE4 compromised the beneficial effects of young plasma. A human induced pluripotent stem cell-derived endothelial cell model recapitulated the plasma apoE isoform-specific effect on endothelial integrity, further supporting a vascular-related mechanism. Upon breeding with amyloid model mice, liver-expressed apoE4 exacerbated brain amyloid pathology, whereas apoE3 reduced it. Our findings demonstrate pathogenic effects of peripheral apoE4, providing a strong rationale for targeting peripheral apoE to treat Alzheimer's disease.
Published: 2022

38. Cu doping effects on the electronic structure of Fe1−xCuxSe

Author: S. Huh, Z. Lu, Y. S. Kim, D. Kim, S. B. Liu, M. W. Ma, L. Yu, F. Zhou, X. L. Dong, C. Kim, and Z. X. Zhao
Published: 2022

39. The expression of BrMDHAR gene in chloroplasts and mitochondria enhances tolerance to freezing stress in Arabidopsis thaliana

Author: S. Y. Shin, Y. S. Kim, I. S. Kim, Y. H. Kim, H. M. Park, and H. S. Yoon
Subjects: ascorbate-glutathione cycle, ascorbate regeneration, brassica rapa, chlorophyll content, dual targeting, pisumsativum, redox homeostasis, ros, transgenic plants, Biology (General), QH301-705.5, Plant ecology, QK900-989
Abstract: In chloroplasts and mitochondria, antioxidant mechanisms include the ascorbate-glutathione cycle, and monodehydroascorbate reductase (MDHAR) is important for regeneration of ascorbate (AsA) from monodehydroascorbate (MDHA). To improve detoxification of reactive oxygen species (ROS), we established a construct of the MDHAR gene from Brassica rapa fused to the targeting signal peptides of Pisum sativum glutathione reductase (GR), which was controlled by a stress-inducible SWPA2 promoter, and introduced this expression system into Arabidopsis thaliana. Transgenic (TG) plants overexpressing BrMDHAR targeted to chloroplasts and mitochondria through signal peptides showed an elevated MDHAR activity and an increased ratio of AsA to dehydroascorbate (DHA) when compared to wild-type (WT) plants under a freezing stress. These led to increased photosynthetic parameters, redox homeostasis, and biomass in TG plants when compared to the WT plants. Our results suggest that the overexpression of the BrMDHAR gene targeted to chloroplasts and mitochondria conferred an enhanced tolerance against the freezing stress, and a stress adaptation of dual-targeted BrMDHAR was better than that of single BrMDHAR.
Published: 2014
Full Text: View/download PDF

40. Study on Growth Curves of Muscle Area, Backfat Thickness and Body Conformation for Hanwoo (Korean Native) Cows

Author: J. H. Lee, S.-H. Oh, Y. M. Lee, Y. S. Kim, H. J. Son, D. J. Jeong, N. C. Whitley, and J. J. Kim
Subjects: Hanwoo, Cows, Growth Curve, Ultrasound, Body Conformation, Animal culture, SF1-1100, Animal biochemistry, QP501-801
Abstract: The objective of this study was to estimate the parameters of Gompertz growth curves with the measurements of body conformation, real-time ultrasound longissimus dorsi muscle area (LMA) and backfat thickness (BFT) in Hanwoo cows. The Hanwoo cows (n = 3,373) were born in 97 Hanwoo commercial farms in the 17 cities or counties of Gyeongbuk province, Korea, between 2000 and 2007. A total of 5,504 ultrasound measurements were collected for the cows at the age of 13 to 165 months in 2007 and 2008. Wither height (HW), rump height (HR), the horizontal distance between the top of the hips (WH), and girth of chest (GC) were also measured. Analysis of variance was conducted to investigate variables affecting LMA and BFT. The effect of farm nested in location was included in the statistical model, as well as the effects of HW, HR, WH, and GC as covariates. All of the effects were significant in the analysis of variance for LMA and BFT (p
Published: 2014
Full Text: View/download PDF

41. A Whole Genome Association Study on Meat Palatability in Hanwoo

Author: K.-E. Hyeong, Y.-M. Lee, Y.-S. Kim, K. C. Nam, C. Jo, K.-H. Lee, J.-E. Lee, and J.-J. Kim
Subjects: Hanwoo, Single Nucleotide Polymorphism, Meat Quality, Palatability, Whole Genome Association, Animal culture, SF1-1100, Animal biochemistry, QP501-801
Abstract: A whole genome association (WGA) study was carried out to find quantitative trait loci (QTL) for sensory evaluation traits in Hanwoo. Carcass samples of 250 Hanwoo steers were collected from National Agricultural Cooperative Livestock Research Institute, Ansung, Gyeonggi province, Korea, between 2011 and 2012 and genotyped with the Affymetrix Bovine Axiom Array 640K single nucleotide polymorphism (SNP) chip. Among the SNPs in the chip, a total of 322,160 SNPs were chosen after quality control tests. After adjusting for the effects of age, slaughter-year-season, and polygenic effects using genome relationship matrix, the corrected phenotypes for the sensory evaluation measurements were regressed on each SNP using a simple linear regression additive based model. A total of 1,631 SNPs were detected for color, aroma, tenderness, juiciness and palatability at 0.1% comparison-wise level. Among the significant SNPs, the best set of 52 SNP markers were chosen using a forward regression procedure at 0.05 level, among which the sets of 8, 14, 11, 10, and 9 SNPs were determined for the respectively sensory evaluation traits. The sets of significant SNPs explained 18% to 31% of phenotypic variance. Three SNPs were pleiotropic, i.e. AX-26703353 and AX-26742891 that were located at 101 and 110 Mb of BTA6, respectively, influencing tenderness, juiciness and palatability, while AX-18624743 at 3 Mb of BTA10 affected tenderness and palatability. Our results suggest that some QTL for sensory measures are segregating in a Hanwoo steer population. Additional WGA studies on fatty acid and nutritional components as well as the sensory panels are in process to characterize genetic architecture of meat quality and palatability in Hanwoo.
Published: 2014
Full Text: View/download PDF

42. 370 Single-Cell Analysis of Human Glioma and Immune Cells Identifies S100A4 as an Immunotherapy Target

Author: Kristin Huntoon, Nourhan Abdelfattah, Caiyi Wang, Parveen Kumar, Wen Jiang, Betty Y. S. Kim, Joshy George, and Kyuson Yun
Subjects: Surgery, Neurology (clinical)
Published: 2023

43. Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntington’s disease mouse model

Author: Sungsu Lim, Sun-Joon Min, Yun Kyung Kim, Younghee Kim, Hyunah Choo, Lizaveta Gotina, Yu Jin Hwang, Hoon Ryu, Y. S. Kim, Ashwini M. Londhe, Jihye Seong, Min Young Lee, Ae Nim Pae, Jieun Kim, Seung Jae Hyeon, Yong Seo Cho, and Hyemyung Seo
Subjects: Cell Survival, Heterochromatin, Mice, Transgenic, RM1-950, Biosensing Techniques, Neuropathology, Biology, Medium spiny neuron, medium spiny neuron, 01 natural sciences, Motor function, Mice, Huntington's disease, Drug Discovery, Fluorescence Resonance Energy Transfer, SETDB1, medicine, Animals, Epigenetics, Enzyme Inhibitors, Cells, Cultured, Neurons, Pharmacology, Behavior, Animal, Molecular Structure, 010405 organic chemistry, motor function, Histone-Lysine N-Methyltransferase, General Medicine, Histone H3K9me3-specific transferase, medicine.disease, Small molecule, 0104 chemical sciences, Disease Models, Animal, 010404 medicinal & biomolecular chemistry, Huntington Disease, Therapeutics. Pharmacology, Neuroscience, Research Article, Research Paper, Huntington’s disease
Abstract: The present study describes evaluation of epigenetic regulation by a small molecule as the therapeutic potential for treatment of Huntington’s disease (HD). We identified 5-allyloxy-2-(pyrrolidin-1-yl)quinoline (APQ) as a novel SETDB1/ESET inhibitor using a combined in silico and in vitro cell based screening system. APQ reduced SETDB1 activity and H3K9me3 levels in a HD cell line model. In particular, not only APQ reduced H3K9me3 levels in the striatum but it also improved motor function and neuropathological symptoms such as neuronal size and activity in HD transgenic (YAC128) mice with minimal toxicity. Using H3K9me3-ChIP and genome-wide sequencing, we also confirmed that APQ modulates H3K9me3-landscaped epigenomes in YAC128 mice. These data provide that APQ, a novel small molecule SETDB1 inhibitor, coordinates H3K9me-dependent heterochromatin remodelling and can be an epigenetic drug for treating HD, leading with hope in clinical trials of HD., Graphical Abstract
Published: 2021

44. A new approach to linearly constrained beamforming for interference cancellation.

Author: Y.-S. Kim, S.-Y. Lee, and D.-Y. Kim
Published: 2001

45. Practices and issues of moulting programs for laying hens: a review

Author: R. Mishra, B. Mishra, Y. S. Kim, and R. Jha
Subjects: Reproduction, Animals, Animal Science and Zoology, Female, General Medicine, Molting, Feathers, Chickens, Food Science, Ovum
Abstract: 1. Moulting is a natural physiological process in birds when they shed their old feathers and replace them with new ones, and it is followed by reproductive quiescence resulting in reduced egg production. Different birds undergo moulting at different points in their life. Some birds have seasonal moulting while some moult at the end of their breeding cycle. This review will mainly focus on moulting practices associated with commercial layer birds because, in all other bird types, this is not managed.2. Commercial farms commonly analyse the cost-benefit ratio to decide the time and method to adopt for moulting. Commercial layer farms adopt different practices to force birds out of moult and restart the production cycle. Animal welfare groups consider this as stressful and against animal welfare, raising questions about the ethics of this practice.3. Many studies have been conducted using complete or partial feed withdrawal and non-feed withdrawal programs to measure their effectiveness in maintaining animal welfare, economy, and post-moult performance in mind.4. Animal welfare should not be compromised during moulting. The United States Egg Producers and other such groups from the United Kingdom and Europe have decided to sell eggs produced only through a non-feed withdrawal moulting programs.
Published: 2022

46. Missing Value Estimation Based on Dynamic Attribute Selection.

Author: K. C. Lee, J. S. Park, Y. S. Kim, and Yung-Tai Byun
Published: 2000
Full Text: View/download PDF

47. New Mechanism on Synergistic Effect of Nitrite and Triethanolamine Addition on the Corrosion of Ductile Cast Iron

Author: K. T. Kim, H. Y. Chang, B. T. Lim, H. B. Park, and Y. S. Kim
Subjects: Materials of engineering and construction. Mechanics of materials, TA401-492
Abstract: In general, we compared the different inhibition mechanisms of organic inhibitor with that of anodic inhibitor. When triethanolamine or nitrite was added separately to tap water for inhibiting the corrosion of ductile cast iron, large amounts of inhibitor were needed. This is because the corrosion inhibitors had to overcome the galvanic corrosion that occurs between graphite and matrix. In this work, we investigated the corrosion of ductile cast iron in tap water with/without inhibitors. The corrosion rate was measured using chemical immersion test and electrochemical methods, including anodic polarization test. The inhibited surface was analyzed using EPMA and XPS. Test solutions were analyzed by performing FT-IR measurement. When triethanolamine and nitrite coexisted in tap water, synergistic effect built up, and the inhibition effect was ca. 30 times more effective than witnessed with single addition. This work focused on the synergistic effect brought about by nitrite and triethanolamine and its novel mechanism was also proposed.
Published: 2016
Full Text: View/download PDF

48. Do Small-Mass Neutrinos Participate in Gauge Transformations?

Author: Y. S. Kim, G. Q. Maguire, and M. E. Noz
Subjects: Physics, QC1-999
Abstract: Neutrino oscillation experiments presently suggest that neutrinos have a small but finite mass. If neutrinos have mass, there should be a Lorentz frame in which they can be brought to rest. This paper discusses how Wigner’s little groups can be used to distinguish between massive and massless particles. We derive a representation of the SL(2,c) group which separates out the two sets of spinors: one set is gauge dependent and the other set is gauge invariant and represents polarized neutrinos. We show that a similar calculation can be done for the Dirac equation. In the large-momentum/zero-mass limit, the Dirac spinors can be separated into large and small components. The large components are gauge invariant, while the small components are not. These small components represent spin-1/2 non-zero-mass particles. If we renormalize the large components, these gauge invariant spinors represent the polarization of neutrinos. Massive neutrinos cannot be invariant under gauge transformations.
Published: 2016
Full Text: View/download PDF

49. Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer’s disease via H2O2− production

Author: Jiwoon Lim, Sunpil Kim, Bong-Kiun Kaang, Hyeonjoo Im, Yongmin Mason Park, Daesoo Kim, Jong Hyun Park, Hoon Ryu, Y. S. Kim, Yujin Hwang, Ki Duk Park, Hyesun Cho, Hansang Cho, Seonmi Jo, Jeong-Sun Seo, Byoung Joo Gwag, Heejung Chun, Seung Eun Lee, Young-Soo Kim, Jaekwang Lee, Doo Yeon Kim, Yeonha Ju, You Jung Kang, Woojin Won, Junsung Woo, Jin Hee Shin, and C. Justin Lee
Subjects: 0301 basic medicine, Programmed cell death, business.industry, General Neuroscience, Transgene, Neurodegeneration, medicine.disease, Pathogenesis, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, medicine.anatomical_structure, Atrophy, medicine, Neuroglia, Tauopathy, Monoamine oxidase B, business, Neuroscience, 030217 neurology & neurosurgery
Abstract: Although the pathological contributions of reactive astrocytes have been implicated in Alzheimer's disease (AD), their in vivo functions remain elusive due to the lack of appropriate experimental models and precise molecular mechanisms. Here, we show the importance of astrocytic reactivity on the pathogenesis of AD using GiD, a newly developed animal model of reactive astrocytes, where the reactivity of astrocytes can be manipulated as mild (GiDm) or severe (GiDs). Mechanistically, excessive hydrogen peroxide (H2O2) originated from monoamine oxidase B in severe reactive astrocytes causes glial activation, tauopathy, neuronal death, brain atrophy, cognitive impairment and eventual death, which are significantly prevented by AAD-2004, a potent H2O2 scavenger. These H2O2--induced pathological features of AD in GiDs are consistently recapitulated in a three-dimensional culture AD model, virus-infected APP/PS1 mice and the brains of patients with AD. Our study identifies H2O2 from severe but not mild reactive astrocytes as a key determinant of neurodegeneration in AD.
Published: 2020

50. Momentum dependent $$d_{xz/yz}$$ d x z / y z band splitting in LaFeAsO

Author: S. S. Huh, Y. S. Kim, W. S. Kyung, J. K. Jung, R. Kappenberger, S. Aswartham, B. Büchner, J. M. Ok, J. S. Kim, C. Dong, J. P. Hu, S. H. Cho, D. W. Shen, J. D. Denlinger, Y. K. Kim, and C. Kim
Subjects: Condensed Matter::Superconductivity, lcsh:R, lcsh:Medicine, lcsh:Q, lcsh:Science
Abstract: The nematic phase in iron based superconductors (IBSs) has attracted attention with a notion that it may provide important clue to the superconductivity. A series of angle-resolved photoemission spectroscopy (ARPES) studies were performed to understand the origin of the nematic phase. However, there is lack of ARPES study on LaFeAsO nematic phase. Here, we report the results of ARPES studies of the nematic phase in LaFeAsO. Degeneracy breaking between the $$d_{xz}$$ d xz and $$d_{yz}$$ d yz hole bands near the $$\Gamma$$ Γ and M point is observed in the nematic phase. Different temperature dependent band splitting behaviors are observed at the $$\Gamma$$ Γ and M points. The energy of the band splitting near the M point decreases as the temperature decreases while it has little temperature dependence near the $$\Gamma$$ Γ point. The nematic nature of the band shift near the M point is confirmed through a detwin experiment using a piezo device. Since a momentum dependent splitting behavior has been observed in other iron based superconductors, our observation confirms that the behavior is a universal one among iron based superconductors.
Published: 2020

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

1,309 results on '"Y-S, Kim"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources